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RESUMO 
A periodontite agressiva é caraterizada por apresentar início precoce, 
rápida progressão e pobre resposta as abordagens terapêuticas quando 
comparado a periodontite crônica. Entretanto, os mecanismos responsáveis por 
essas diferenças ainda não são completamente compreendidos. Ferramentas 
como a genômica, proteômica ou transcriptômica podem esclarecer esses 
aspectos, gerando importantes informações a respeito da patogênese das 
doenças periodontais. Portanto, os objetivos do presente estudo foram: i) 
Apresentar uma revisão de literatura focada na aplicação da genômica, 
transcriptômica, proteômica e metabolômica no estudo das doenças periodontais. 
ii) Avaliar as diferenças no perfil de expressão gênica da mucosa mastigatória, 
sem a influência do biofilme subgengival, em indivíduos com histórico de 
periodontite agressiva e crônica, comparando-os entre si e também com o perfil de 
expressão de indivíduos sem histórico de periodontite visando à identificação de 
possíveis alterações constitutivas na expressão de genes que podem estar 
relacionadas com as diferenças entre as duas formas de periodontite. Para o 
primeiro objetivo, foi realizada uma revisão dos artigos que empregaram as 
tecnologias ômicas no estudo das doenças periodontais. Os estudos presentes na 
literatura indicaram que essas tecnologias podem levar a um melhor entendimento 
dos eventos moleculares envolvidos na patogênese das doenças periodontais. 
Para o segundo objetivo, foram obtidas amostras teciduais da mucosa 
mastigatória de 4 pacientes com histórico de periodontite crônica, 4 com 
periodontite agressiva generalizada e 4 indivíduos sem histórico de periodontite. 
As amostras foram manipuladas para a extração de RNA total, síntese de cDNA 
de fita dupla e a hibridização por microarranjo de DNA, avaliando a expressão de 
45033 genes. Os programas R e Bioconductor foram empregados para realizar a 
análise de RMA (Robust-Multi-Array), calcular o valor de expressão (fold-change) 
e o valor de p para comparações múltiplas através do método de Benjamini-
Hochberg. O enriquecimento dos dados, através de ontologia gênica e análise de 
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via, foi realizado com o programa de bioinformática DAVID (Database for 
Annotation, Visualization and Integrated Discovery). Três comparações foram 
realizadas: comparação 1 (periodontite agressiva x indivíduos sem histórico de 
periodontite); comparação 2 (periodontite crônica x indivíduos sem histórico de 
periodontite); e comparação 3 (periodontite crônica x periodontite agressiva). A 
comparação entre os grupos identificou: 192 genes e 50 grupos diferencialmente 
expressos na comparação 1, 43 genes e 27 grupos na comparação 2 e 168 genes 
e 75 grupos na comparação 3. Genes com funções no sistema imune, entre os 
quais receptores de linfócitos natural killer, foram mais expressos em periodontite 
agressiva; em contraste, genes envolvidos na proliferação e diferenciação de 
queratinócitos, assim como genes com função em processos neurais foram menos 
expressos. Já os indivíduos com periodontite crônica se caracterizaram por um 
aumento na expressão de genes com função na resposta a estímulos externos, e 
uma diminuição na expressão dos genes relacionados ao sistema imune. Dentro 
dos limites desse estudo, pode-se concluir que existem diferenças nos perfis de 
expressão gênica da mucosa mastigatória de indivíduos com histórico de 
periodontite agressiva e crônica, quando comparadas entre si e com indivíduos 
sem histórico de periodontite, que podem estar associadas às diferenças em suas 
patogêneses.  
 
Palavras-chave: Periodontite agressiva; Periodontite crônica; 
Biologia molecular; Expressão Gênica; Susceptibilidade a doenças. 
 
 
 
 
 
 
 
  
xv 
 
ABSTRACT 
 
Aggressive periodontitis is characterized by early onset, rapid 
progression and poor response to treatment compared to chronic periodontitis. 
However, mechanisms responsible for these differences are not fully understood. 
Tools such as genomics, proteomics and transcriptomics can clarify these aspects, 
producing important information about the pathogenesis of periodontal diseases. 
Therefore, the aims of this study were: i) Provide a literature review focused on the 
application of genomics, transcriptomics, proteomics, and metabolomics in the 
study of periodontal diseases. ii) Evaluate the gene expression profile of tissue 
from masticatory mucosa, without the influence of biofilm, in patients with a history 
of generalized aggressive and chronic periodontitis, and also with gene expression 
profile of individuals without periodontitis, with the aim to identify possible 
constitutive alterations in gene expression, which may be related to the differences 
between both forms of periodontitis. For the first objective, it was performed a 
review of articles that employed omics technologies in the study of periodontal 
diseases. The studies in the literature indicated that theses technologies can lead 
to a better understanding of molecular events involved in the pathogenesis of 
periodontal diseases. For the second objective, masticatory mucosa tissue 
samples were obtained from 4 patients with a history of chronic periodontitis, 4 with 
generalized aggressive periodontitis, and 4 from subjects without history of 
periodontitis. Tissue samples were processed for total RNA extraction, double-
strand cDNA synthesis for subsequent hybridization reaction on microarrays, which 
assessed the expression of 45033 genes. R and Bioconductor softwares used to 
perform the RMA analysis (Robust Multi-Array), calculate the value of expression 
(fold-change) and the p-value for multiple comparisons through Benjamini-
Hochberg method. Enrichment analysis, through gene ontology (GO) and pathway 
analysis, was performed with DAVID (Database for Annotation, Visualization and 
Integrated Discovery). Three comparisons were performed: comparison 1 
(aggressive periodontitis x healthy subjects); comparison 2 (chronic periodontitis x 
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healthy subjects); and comparison 3 (chronic periodontitis x aggressive 
periodontitis). Comparisons analysis found 192 genes and 50 groups differentially 
expressed in comparison 1, 43 genes and 27 groups in comparison 2, and 168 
genes and 75 groups in comparison 3. Genes with function in the immune system, 
including natural killer cells receptors, were higher expressed in aggressive 
periodontitis; in contrast, genes involved in proliferation and differentiation of 
keratinocytes, as well as genes with function in neural process were lower 
expressed. Chronic periodontitis subjects were characterized by increased 
expression of genes related to response to external stimuli, and a decrease in the 
expression of genes related to the immune system. Within the limits of this study, it 
can be concluded that there are differences in the gene expression profile of 
masticatory mucosa of patients with a history of chonic and aggressive 
periodontitis, when compared among them and with healthy group, which may be 
associated with differences in their pathogenesis.  
 
Key words: Aggressive periodontitis; Chronic periodontitis; 
Molecular biology; Gene expression; Disease susceptibility. 
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Introdução 
A periodontite é uma doença inflamatória de etiologia multifatorial, 
caracterizada pela destruição óssea e perda de inserção conjuntiva (Feng & 
Weinberg, 2006). A destruição do suporte periodontal, em sua maior parte, é 
resultado da resposta imune-inflamatória do hospedeiro aos periodontopatógenos 
(Socransky & Haffajee, 2005). Estudos epidemiológicos apontam que a 
periodontite crônica tem maior prevalência, afetando mais de 50% da população, 
enquanto que os indivíduos diagnosticados com periodontite agressiva 
representam 1 a 15% da população (Demmer & Papapanou, 2010). 
Embora a periodontite crônica e a agressiva aparentemente derivam 
dos mesmos fatores etiológicos, elas apresentam diferenças claras no seu 
desenvolvimento e progressão (Tonetti & Mombelli, 1999). Enquanto a periodontite 
crônica apresenta uma progressão lenta, usualmente compatível com os fatores 
locais, a periodontite agressiva é definida como uma doença inflamatória de início 
precoce, acometendo geralmente indivíduos jovens, caracterizada pela rápida 
perda de inserção e destruição óssea (Armitage, 1999). Visando uma melhor 
compreensão dos fatores envolvidos na patogênese destas doenças e tentando 
explicar possíveis diferenças entre as formas crônica e agressiva da periodontite, 
aspectos microbiológicos, imunológicos e genéticos têm sido estudados; 
entretanto os mecanismos responsáveis por essas diferenças ainda não foram 
completamente explicados (Kinane et al., 1999; Armitage, 2002; Casarin et al., 
2010).  
Na tentativa de esclarecer essas dúvidas, novas abordagens como a 
genômica, transcriptômica, proteômica e metabolômica tem sido utilizadas para se 
avaliar os mecanismos envolvidos na patogênese da doença periodontal. De fato, 
alguns estudos avaliaram o transcriptoma do tecido gengival e de células 
mononucleares da circulação periférica de pacientes com periodontite (Papapanou 
et al., 2004; Beikler et al., 2008; Demmer et al., 2008; Sorensen et al., 2008; 
Papapanou et al., 2009). Sorensen et al. (2008) avaliaram a expressão gênica de 
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monócitos e linfócitos da circulação periférica de pacientes com periodontite 
agressiva localizada e generalizada, demonstrando que o perfil de expressão 
gênica na periodontite agressiva localizada foi homogêneo, enquanto na 
periodontite agressiva generalizada a expressão gênica foi heterogênea, indicando 
uma entidade patológica mais complexa e variável (Sorensen et al., 2008). 
Em 2004, em um estudo piloto, Papapanou et al. utilizando a técnica de 
microarray (microarranjo de DNA) para avaliar a expressão gênica do tecido 
gengival inflamado de pacientes com periodontite crônica e agressiva, não 
encontraram diferenças significativas na expressão gênica entre os dois tipos de 
periodontite. Empregando a mesma tecnologia, Demmer et al. (2008) avaliaram a 
expressão gênica entre tecidos gengivais sadios e acometidos por doença 
periodontal, anterior a qualquer intervenção terapêutica, não fazendo distinção 
entre as formas crônica e agressiva. Os resultados mostraram que da análise do 
transcriptoma, 12744 genes foram diferencialmente expressos, sendo que 5295 
foram mais expressos e 7449 foram menos expressos nos tecidos acometidos por 
periodontite. Da mesma maneira a análise por ontologia gênica revelou que 61 
grupos (incluindo apoptose, resposta humoral antimicrobiana, apresentação de 
antígenos, regulação do processo metabólico e angiogênese) foram 
diferencialmente expressos nos tecidos doentes, indicando o envolvimento de um 
amplo número de genes e, consequentemente, de seus mecanismos 
intracelulares. A despeito desses estudos, genes específicos relacionados à 
doença periodontal ainda não foram identificados. 
Entretanto, deve-se ressaltar que os resultados da análise de 
expressão gênica dos tecidos gengivais podem ser influenciados pela composição 
da microbiota, pelo grau de inflamação tecidual, por fatores ambientais, por fatores 
genéticos e epigenéticos (Demmer et al., 2008; Kornman, 2008; Papapanou et al., 
2009). Dessa forma, para determinar diferenças entre distintos perfis de doença, 
devem-se considerar alterações constitutivas que podem estar presentes nesses 
indivíduos, ou seja, avaliar a expressão gênica quando essas variáveis estão 
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ausentes. Essa avaliação permitiria determinar alterações que podem estar 
relacionadas a alterações genéticas dos indivíduos ou alterações do controle 
celular individual (Kinane et al., 2006; Takashiba & Naruishi, 2006; Stabholz et al., 
2010; Nahid et al., 2011). Além disso, é importante compreender que o perfil de 
expressão gênica dos tecidos sadios e intactos de indivíduos com periodontite 
pode apresentar diferenças se comparados aos sítios saudáveis de indivíduos que 
não tiveram experiência de periodontite (Demmer et al., 2008).  
Nesse contexto, a avaliação do perfil de expressão gênica da mucosa 
mastigatória, sem a influência da microbiota na expressão gênica tecidual, pode 
permitir a identificação de possíveis alterações dos mecanismos da fisiologia 
tecidual, próprios dos indivíduos, que possam ser traduzidos em um perfil de maior 
susceptibilidade ao desenvolvimento das doenças periodontais. Esse tipo de 
análise se justifica uma vez que a presença de bactérias na região do sulco 
gengival, mesmo aquelas compatíveis com a saúde periodontal, exercem uma 
influência na expressão gênica tecidual (Papapanou et al., 2009), impossibilitando 
a análise das características relacionadas apenas com o indivíduo. 
Portanto, os objetivos do presente estudo foram: i) apresentar uma 
revisão de literatura focada na aplicação da genômica, transcriptômica, proteômica 
e metabolômica no estudo das doenças periodontais. ii) analisar o perfil de 
expressão gênica da mucosa mastigatória, sem influência do biofilme, de 
pacientes com histórico de periodontite crônica e agressiva, comparando-os entre 
si e também com o perfil de expressão de indivíduos sem histórico de periodontite. 
Descrevendo os genes, as classes e as vias que tais genes pertencem, com 
expressão diferenciada entre os grupos. 
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Capítulo 1 
 
The potential use of molecular approaches for diagnosis in 
periodontics: the role of omics knowledge  
Submetido ao periódico DNA and Cell Biology. 
Running title: Molecular diagnosis of periodontal disease 
Keywords: periodontitis; biomarkers; genomics; transcriptomics; 
proteomics; metabolomics 
Tiago Taiete1, Renato Corrêa Viana Casarin1,2, Karina Gonzales 
Silvério1, Enilson Antonio Sallum1, Francisco Humberto Nociti-Jr1, Márcio Zafallon 
Casati1,2 
1 Department of Prosthodontics and Periodontics, Piracicaba Dental School, 
State University of Campinas, Piracicaba, São Paulo, Brazil 
2 Department of Periodontics, University Paulista, São Paulo, São Paulo, Brazil 
Corresponding Author: Márcio Zafallon Casati – email: 
casati@fop.unicamp.br Fax number +55 19 21065301. Address: 901 Limeira 
avenue, Areião, São Paulo, Brazil, ZC 13414-903 
Abstract 
Periodontal diseases are highly complex and have multifactorial etiology 
processes with the participation of several biological mechanisms. This review 
sought to discuss some of the advances in scientific research that use molecular 
biology methods to address the aspects of genomic, proteomic, transcriptomic, and 
metabolomic of periodontal diseases. Several studies in the literature show that 
these tools aim to promote a better understanding of the mechanisms involved in 
the pathogenesis and identification of new biomarkers of periodontal diseases that 
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may be used in future diagnostic tests to detect the presence of active disease, 
predict future progression, and evaluate the response to periodontal therapy. 
 
 
Introduction 
Periodontitis is a group of chronic inflammatory diseases affecting the 
teeth and supporting tissues, including the alveolar bone (Dennison and van Dyke, 
1997; Sørensen et al., 2008). It is one of the most common causes of tooth loss in 
adults (Chung et al., 2009). The disease develops when there is an imbalance 
between the microbial challenge and host immune-inflammatory response, with its 
clinical expression altered by important environmental and host-modifying 
conditions (Quirynen et al., 2001; Armitage, 2002). 
Although the knowledge about the pathology pathways has grown 
rapidly in recent decades, the underlying mechanisms of many diseases remain 
obscure (Burke, 2003), including periodontal diseases. Chronic and aggressive 
periodontitis diseases appear to derive from the same etiologic factors, they 
present clear differences in their development and progression (Tonetti and 
Mombelli, 1999); however, the mechanisms responsible for these differences 
remain unknown (Kinane et al., 1999; Casarin et al., 2010). In addition, it is highly 
probable that chronic periodontitis or aggressive periodontitis diseases are not a 
single entity, but constellations of polymicrobial and polygenic infections, and 
possibly with different mechanisms of pathogenesis (Armitage, 2002; Dentino et 
al., 2013). However, the clinical parameters currently used for diagnosis of 
periodontal diseases, such as pocket depth and bleeding on probing, are poor 
reflections of the pathobiology of the various forms of periodontitis and are not 
specific or reliable for diagnosis (Armitage, 2004; Taba et al., 2005; Demmer et al., 
2008). In this respect, some studies have attempted to identify the characteristics 
indicative of the pathogenic process status with greater accuracy, i.e., biomarkers. 
These biomarkers could be used in order to facilitate the early diagnosis of the 
active phases of periodontal disease and the identification of patients at risk of 
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future development of the disease (de Souza and Taba, 2004; Taba et al., 2005; 
Demmer et al., 2008). 
Biomarkers are defined by National Institutes of Health (NIH, USA) as ‘a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biologic process, pathogenis processes, or pharmacologic responses to a 
therapeutic intervention’. Many of the agents involved in the pathogenesis of 
periodontal diseases, including substances derived from host (such as cytokines, 
enzymes, antibodies, and products from tissue breakdown) and/or microbial factors 
(such as specific harboring-pathogens in the subgingival environment), may be 
identified at different levels (depending on the type, severity, and disease activity) 
in the gingival crevice fluid, saliva, and gingival tissue (Taba et al., 2005). All of 
them could be considered potential biomarkers. According to Taba et al. (2005) 
there are several diagnostic tools to measure periodontal disease at the molecular, 
cellular, and tissue levels, including polymerase chain reaction (PCR), DNA-DNA 
hybridization, and enzyme-linked immunoabsorbent assay (ELISA), among others. 
However, to date, there is no practical and accurate periodontal indicator based in 
these analyses (Uitto, 2003). 
With the advances in scientific research and the development of new 
techniques providing the chance to study genomic, transcriptomic, proteomic, and 
metabolomic capabilities, our understanding of the onset, progression, and 
pathogenic process involved in periodontal diseases has greatly expanded, thus 
increasing our possibility of identifying biomarkers of periodontal diseases (Taba et 
al., 2005; Kormman, 2008). In this sense, this review summarizes some of these 
advances in research using molecular biology techniques, such as genomic, 
transcriptomic, proteomic, and metabolomics to evaluate the characteristics of the 
host. These techniques might eventually lead to new diagnostic tests for 
periodontal diseases. 
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Genomics 
Genomics refers to the study of the entire genome of an organism, i.e., 
all the DNA of a single organism. Technological breakthroughs in genomic 
research, such as improvements in DNA-sequencing, SNPs microarray, and 
genome-wide association study, allow assessing thousands of genes and their 
association with disease-related events (Burke, 2003; Schäfer et al., 2011). Its 
development has the potential to change the practice of health sciences, 
particularly dentistry (Giacomelli and Covani, 2010; Grant, 2012). 
Genetic variations are mainly the SNPs (single nucleotide 
polymorphisms), that can affect gene expression or the functions of protein 
produced (Takashiba and Naruishi, 2006). In periodontics, for some time genetic 
studies evaluated the relationship between the presence of individual gene 
polymorphisms of cytokines, immuno-receptors, human leukocyte antigens (HLA), 
and others and the risk of onset and severity of periodontal diseases, as well as 
the result of periodontal treatment (Takashiba and Naruishi, 2006; Grant, 2012). 
Many studies have reported a positive association between 
polymorphisms of the interleukin (IL)-1 gene and periodontal diseases. Kornman et 
al. (1997) reported an association between polymorphisms in the genes encoding 
IL-1α (-889) and IL-1β (+3953) and an increased severity of periodontitis, with 
other studies showing similar results. Gore et al. (1998) also reported a possible 
role of IL-1α and IL-1β gene polymorphisms in the susceptibility to adult 
periodontitis. On the other hand, Papapanou et al. (2001) in a study of 132 
periodontitis patients who were age- and sex-matched with controls did not show 
any association with the composite genotype and periodontitis. Meisel et al. (2002) 
stated that the composite genotype showed a strong interaction with smoking, 
whereas non-smokers, even genotype-positive, were not at increased risk, 
suggesting that genetic–environmental interaction is more important than genetic 
factors alone for the determination of susceptibility to periodontitis. 
Schäefer et al. (2010) published the first genome-wide association study 
in periodontics. In this study, examining 500,568 potential SNPs in 141 generalized 
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aggressive periodontitis patients and 142 localized aggressive periodontitis 
patients independently identified 197 and 244, respectively, quality-controlled 
SNPs. However, when the results from both sets were compared, only one SNP rs 
1537415 located whithin intron 2 of GLT6D1 gene remained significant, which was 
subsequently validated in a third set of patients. GLT6D1 gene encodes for an 
ezyme glycosiltransferase 6 family, single-pass transmembranes proteins. These 
enzymes contribute to the synthesis of histo-blood related antigens in the Golgi. 
GLT6D1 had strong expression in leukocytes and gingival connective tissue and 
may influence immune responses. 
Divaris et al. (2012) performed a genome-wide association analysis 
investigating risk loci for a high colonization with pathogenic periodontal bacteria, in 
1020 white subjects, and in a second step to validate their results, in samples of 
123 African American. In white subjects 13 loci (including genes involved in MMP-
13 expression, macrophage adhesion and migration, and interleukin—33 
production) provide suggestive evidence for high colonization with red complex, 
orange complex, and Aggregatibacter actinomycetemcomitans (Aa). In African 
American associations reported for red and orange complex microbiota, but not for 
Aa, had the same effect direction. These findings lead to and improved 
understanding of the host-microbiome interactions in periodontitis. 
To date, although some associations were identified between gene 
polymorphisms and periodontal disease, there is limited evidence for most of the 
genes studied (Kinane and Hart, 2003; Schäfer et al., 2011). Futures studies using 
high thoughput technologies, such as genome-wide association studies, in a larger 
numbers of patients and control subjects may yield more associations. Thereby, 
improving the understanding of disease process, and easing diagnostic, which may 
allow to stratify patients according to the disease risk (Schäfer et al., 2011; Grant, 
2012; Sleiman and Termatchi, 2013). 
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Transcriptomic 
Transcriptomic is defined as the study of the set of all RNAs transcribed 
from a cell or tissue in a particular condition that provides their gene expression 
profile (Kebschull and Papapanou, 2010). The study of pathological features of 
periodontal disease by analyzing the gene expression profile may increase the 
understanding of biological events involved in the development of periodontitis 
(Giacomelli and Covani, 2010; Kebschull and Papapanou, 2010). This form of 
technology and assessment has provided important information in the medical 
area, particularly in the research of the pathogenesis of tumors and cancer 
(Quackenbush, 2006), muscular dystrophy (Haslett and Kunkel, 2002), Alzheimer’s 
disease and dementia (Colangelo et al., 2002), and other diseases. The microarray 
technology is the most common method used to study the gene expression profile 
(Wang et al., 2003), and it can be performed to investigate a group of genes with 
specific functions, ranging from a few hundred genes, to over 22000 to 44000 
transcripts which covers the whole transcriptome. 
In the context of periodontal diseases, studies have evaluated the gene 
expression profile of gingival tissue and peripheral blood mononuclear cells from 
patients with periodontitis. Sørensen et al. (2008) evaluated the gene expression 
profile from the peripheral blood mononuclear cells of patients with both localized 
aggressive periodontitis and generalized aggressive periodontitis, compared to 
healthy subjects (control group). Fifty-three genes had altered expression in 
patients with localized aggressive periodontitis compared to control, and 14 of 
these were involved in immune response. On the other hand, patients with 
generalized aggressive periodontitis showed a gene expression profile similar to 
control subjects, with only three genes with differential expression, indicating a 
more heterogeneous disease entity (Sørensen et al., 2008). 
In a pilot study, Papapanou et al. (2004) reported that it was possible to 
separate patients with chronic and aggressive periodontitis through the gene 
expression profile of inflamed gingival tissue into two groups, regardless of clinical 
diagnosis. These groups had similar clinical periodontal status and subgingival 
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bacterial profiles, but differed significantly with respect to serum IgG levels against 
the important periodontal pathogens Porphyromonas gingivalis, Tannerella 
forsythia and Campylobacter rectus. Interestingly, differential diagnosis between 
chronic and aggressive periodontitis could not be done. 
Demmer et al. (2008) evaluated the gene expression of inflammed 
gingival tissue adjacent to periodontal pockets of patients with chronic and 
aggressive periodontitis in comparison to healthy gingival tissue. Several genes, 
including those responsible for apoptosis, humoral response, antigen presentation 
and angiogenesis, were differently expressed in periodontal health and disease. It 
could be related to microbial profile in periodontal pocket, as observed by 
Papapanou et al. (2009). In this study, the analysis of the effect of the periodontal 
pathogens in the gene expression of adjacent gingival tissue, showed that the 
expression of certain genes were correlated to bacterial load, somehow modulating 
pathogenesis of disease. However, the pathway of this relationship still remained 
not fully explained. 
Assessing possible factors that influenced the patient response to 
periodontal treatment, Kim et al. (2006) showed that 68 genes were positively and 
6 genes were negatively modulated in sites with refractory periodontitis, compared 
to individuals who responded adequately to periodontal treatment. Most of these 
genes have immune-inflammatory functions. In this way, Beikler et al. (2008) 
investigated gene expression changes in gingival tissue in residual pockets ≥ 7mm, 
after a session of periodontal treatment of patients with chronic periodontitis. The 
authors found that periodontal treatment promotes a strong negative regulation of 
immune-inflammatory response and activates pathways that regulate tissue 
damage and repair. They suggested that these differentially expressed genes can 
be targets for new diagnostic and treatment strategies, and could be used to 
explain the negative clinical response of some specific periodontal conditions. 
In summary, it has been postulated that different patterns of gene 
expression, as the measurement of various biomarkers, could define periodontal 
status with different clinical implications. However, more studies are needed to 
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elucidate this information (Offenbacher et al., 2007; Kormman, 2008). Complete 
information of the gene expression profile of tissues affected by the disease, which 
is influenced by genetic and constitutive characteristics from subjects, microbiota 
composition, environmental factors, and other modifying factors, can provide 
details of molecular networks involved in the affected tissues, concomitantly 
leading to the development of new preventive and therapeutic approaches (Hood 
et al., 2004; Kormman, 2008). 
 
Proteomics 
The goal of proteomics is to identify, quantify, and analyse the locations 
and interactions of the ensemble of expressed proteins in a cell, tissue or fluid in 
normal and diseased conditions (Garcia and Tabak, 2008). Proteomics should also 
be applied to reach a deeper understanding of the molecular mechanisms 
underlying oral disorders (Giacomelli and Covani, 2010), and could assume great 
importance during diagnosis, because proteins are the key functional components 
of biochemical systems and the cellular targets of therapeutics agents (Agrawal et 
al., 2012).  
Proteomics development has been made possible by advances in 
protein sequencing by mass spectrometry and the accompanying separation 
techniques, including electrophoresis and non gel based techniques, such as liquid 
chromatography tandem mass spectrometry (LC-MS/MS), quantitative proteomics 
by mass spectrometry and isobaric tags for relative and absolute quantitation 
(iTRAQ), and fluorescence-based detection technologies (Tyers and Mann, 2003; 
Grant et al., 2010). 
Analyses of salivary proteins have shown that differences in the salivary 
protein profile are associated with oral pathologies, such as chronic and aggressive 
periodontitis, oral lichen planus, and oral cancer (Gonçalves et al., 2011). Wu et al. 
(2009) investigated whether salivary proteomics technology can be used to 
evaluate the disease progression of periodontitis, and identified 11 proteins 
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showing a different expression in saliva of generalized aggressive periodontitis 
patients compared to healthy controls. 
Using saliva proteome to understand the changes after periodontal 
treatment, Haigh et al. (2010) showed that 11 proteins were more abundant in 
individuals with active disease, while 4 proteins decreased on average. In this 
study, most of the altered proteins (haptoglobin, prolactin inducible protein, and 
parotid secretory protein) were associated with host defense. 
The content of gingival crevice fluid can also be assessed by proteomic 
methods, indicating a more local analysis in periodontal disease, i.e., periodontal 
pocket. Kojima et al. (2000), through separation of proteins by two-dimensional 
electrophoresis and protein identification by mass spectrometry, evaluated proteins 
in gingival crevice fluid from periodontitis patients. They reported a distinct pattern 
of proteins in health and periodontal diseases, showing the presence of two 
calcium-binding proteins, calgranulin A (MRP8) and calgranulin B (MRP14) in 
periodontitis sites, which had previously been linked to neurological inflammation 
and neoplastic diseases (Kojima et al., 2000). Lundy et al. (2005) used mass 
spectrometry to assess the presence and quantity of human neutrophil α-defensins 
(human neutrophil peptides) in the gingival crevice fluid of patients with periodontal 
disease compared to healthy subjects. They found higher levels of defensins in 
sites with periodontal health. According the authors, there was a more intact 
defensin barrier in periodontal health related to some immune conditions against 
periodontitis. 
Recent studies employed high-throughput proteomic techniques to 
enhance understanding of the proteins and molecular pathways involved in gingival 
inflammation. Grant et al. (2010) assessed quantitatively the changes in GCF 
proteome profiles in the experimental gingivitis using iTRAQ labeled samples and 
Fourier transform ion cyclotron resonance (FTICR) mass spectrometry. They 
identified 186 human and 16 bacterial proteins throughout the period of 
experimentally induced gingivitis, including proteins displaying antibacterial 
properties, DNA binding, cytoskeleton, and neuronal and synapse associated 
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proteins, which were associated with changes to the clinical parameters. Similarly, 
Bostanci et al. (2013) using liquid chromatography-tandem mass spectrometry for 
label-free quantitative proteomics, analyzed sequential protein expression in 
gingival crevicular fluid samples during the induction and resolution of experimental 
gingivitis. Proteins involved in immune response and antimicrobial function were 
upregulated in induction of gingivitis, such as as alpha-amylase 1, calgranulin A, 
cystatins, lysozyme C, and Cathepsin G. In resolution period several histones, 
immune response-related and neutrophil-derived antibacterial proteins including 
cathepsin G, myeloperoxidase, alpha enolase, and defensin-1 were 
downregulated. 
Bostanci et al. (2010) assessed the composition of GCF of generalized 
aggressive periodontitis subjects by liquid chromatography-mass spectrometry. 
The proportion of enzymes associated with polymorphonuclear neutrophils, such 
as matrix metalloproteinase-8 (MMP-8), cathepsin G, myeloperoxidase, and 
bacterial, viral, and yeast protein was increased in disease compared to health. 
While host defense-related proteins, such as Cystatin-B and defensins, were 
detected only in health.  
Differing from the analysis of DNA and RNA that may benefit from the 
amplification stages of the molecules before the analytical procedures, in 
proteomics it is not often possible to analyze the whole proteome. In addition, it is 
often necessary the removal or separation of some proteins that are abundantly 
found, such as albumin, prior to analytical procedures (Grant, 2012), and its 
presence could mask analysis results. Regardless of the advances in analytical 
techniques, further technological improvements, organization of international 
proteomics projects, and open access to results are needed for proteomics to fulfill 
its potential. 
Comprehensive proteomic analysis complements other “-omics” 
approaches allowing more detailed investigation to find composites of proteins that 
could be used as biomarkers of periodontitis in diseased tissue and fluids, which 
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would facilitate the diagnosis and therapeutic monitoring and understanding of 
host-pathogen interactions. 
 
Metabolomics 
Metabolomics is a discipline that monitors the quantities of all chemicals, 
such as lipids, sugars, and amino acids except, DNA, RNA, and proteins, involved 
within a sample in order to understand metabolic dynamics associated with 
conditions such as a disease or drug exposure (Garcia and Tabak, 2008; 
Giacomelli and Covani, 2010; Spielmann and Wong, 2011; Grant, 2012). 
Metabolomics methodologies are evolving (Garcia and Tabak, 2008), however, no 
single experimental technique can analyze all chemical structures. Therefore, 
samples are analyzed by several techniques, including nuclear magnetic 
resonance and mass spectrometry (Grant, 2012). 
Metabolomics is a promising technique for improved disease screening, 
diagnosis, and prognosis, but there are very few articles that reported the 
assessment of the metabolome in periodontal disease (Garcia and Tabak, 2008). 
In others areas, this approach provide essential information about various chronic 
and multifactorial diseases such as cardio-vascular disease, diabetes, and 
diseases of the central nervous system (Tanke, 2007). 
Barnes et al. (2009) performed a metabolomics profiling of gingival 
crevice fluid (GCF) collected from healthy, gingivitis, and periodontitis sites from 22 
chronic periodontitis subjects by liquid and gas chromatography mass 
spectrometry. Based on the chemical reference library, 103 metabolites were 
detected and from them approximately 50% of the detected metabolites showed 
altered levels among the three periodontal conditions. The authors also 
demonstrated that the purine degradation pathway, a major biochemical source for 
reactive oxygen production, was significantly accelerated at the diseases’ sites, 
suggesting that periodontal disease induces oxidative stress and inflammation 
(Barnes et al., 2009; Grant, 2012). 
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Gronert et al. (2004) used lipidomics, which is a type of metabolomics, to 
investigate the role of lipids in cellular function. They investigated and quantified 
diacylglycerol (DAGK) species in neutrophils from localized aggressive 
periodontitis patients and reported low levels of this molecule that could lead to an 
increase in superoxide anions production. 
The concentration and fluxes of small molecules present in cells, 
tissues, organs, and biologic fluids, described by metabolomics, result from a 
complex interaction between the gene and protein expression and are influenced 
by environment interactions. The results from metabolomics analyses complement 
the information obtained from other “-omics” methodologies, which may improve 
the understanding of the biological basis of the disease (Sugimoto et al., 2010). 
However, additional studies using advanced methods of metabolite 
quantification and more sophisticated data processing and analysis strategies for 
integrating the knowledge obtained from other “-omics” studies are needed to 
increase the understanding of the pathogenesis of periodontal diseases as well as 
to evaluate whether measurements provide a relevant impact on the disease 
diagnosis. 
 
Systems Biology 
Advances in the genomic, proteomic, transcriptomic, and metabolomic 
technologies enabled a better explanation of the molecular networks that are 
involved in specific gene-environment interactions. Analysis of massive amounts of 
information of all the molecules involved in a given process and the interactions 
between these molecules appears to be an enormous task (Kormman, 2008; 
Giacomelli and Covani, 2010). Bioinformatics can become an added value in this 
context. According to Giacomelli and Covani (2010) bioinformatics is defined as the 
application of information technology to the field of molecular biology through the 
development of original algorithms. 
This approach is cited in the literature as system biology; that is, the 
computational integration of data generated by the set of genetic, transcriptomic, 
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proteomic, and metabolomic platforms to understand functions through different 
levels of biomolecular organization though the reconstruction of the complex 
network involved (Nicholson and Wilson, 2003; Fukushima et al., 2009; Grant, 
2012). According to Hood (2004) in a review, system biology is a scientific 
discipline that endeavors to quantify all of the molecular elements of a biological 
system to assess their interactions and to integrate that information into graphical 
network models that serve as predictive hypothesis to explain emergent behaviors. 
Considering the idea that is beginning to revolutionize medicine is that disease 
may perturb the normal network structures of a system through genetic 
perturbations and/or by pathological and environmental changes. With this in mind, 
gene, protein, and metabolic expression profiling could reveal those changes 
(Papapanou et al., 2009). 
The pathophysiology of periodontitis is characterized by the involvement 
of various biologic pathways (Covani et al., 2008). The identification and the 
characterization of candidate genes, proteins, and molecules involved in a given 
disease by the integrated use of “-omics” disciplines will probably represent one of 
the milestones of future health care (Giacomelli and Covani, 2010). The analysis of 
the complex network of connections between genes/proteins may allow the 
identification of potential molecular markers and targets (Giacomelli and Covani, 
2010). 
An example of this approach applied to periodontics is the study of 
Covani et al. (2008) that searched through the published articles and identified 61 
genes potentially involved in periodontitis. Analysis was performed by 
bioinformatics approaches for predicting possible leader genes, i.e., genes that 
may be supposed to play an important role in the analyzed processes, reporting 
that five genes were identified as leader genes (NFκB1, RELA, PIK3R1, GRB2, 
and CBL). These genes are predominantly involved in receptor-mediated signaling 
of the host inflammatory-immune system. 
The results achieved through “-omics” technologies, and the integration 
of the results by bioinformatics approaches will allow a better understanding of the 
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events that occur in the pathogenesis of periodontal disease, and may lead to the 
identification of new risk factors, biomarkers, and therapeutic targets. 
 
Conclusion 
To conclude, there is a vast literature on biomarker research in 
periodontal disease. However, there are still no biomarkers that can be used 
accurately in clinical practice. Improvements in the research techniques, as those 
that employ ‘-omics’ disciplines, may lead to a better understanding of pathogenic 
events of periodontal disease, providing a comprehensive view of the disease 
process through identification of molecules and pathways involved in the shift from 
health to disease and in different pathogenic process. Consequently, they can be 
applied in future diagnosis of periodontal disease through identifying one or more 
biomarkers for the detection of the presence of active disease, predict future 
disease progression, and evaluate the response to periodontal therapy, thereby 
improving the clinical management of periodontal patients through personalized 
healthcare aiming at early prediction and intervention. However, more research is 
needed before these diagnostic tools become a reality in clinical practice. 
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Capítulo 2 
 
Gene expression profiles in healthy masticatory mucosa 
of aggressive and chronic periodontitis 
 
Abstract 
Background and Objective: Gene-expression profiling, a powerful tool to 
generate comprehensive genome-level data sets, have recently been applied to 
study the pathobiology of periodontitis, however, genes responsible for the 
aggressive periodontitis have not been identified. The aim of the present study was 
to investigate the gene expression profile of healthy masticatory mucosa in 
subjects with a history of generalized aggressive periodontitis, chronic 
periodontitis, and who have not experienced destructive periodontitis. 
Material and Methods: Healthy masticatory mucosa were taken from 
four well-maintained patients with a  history of generalized aggressive periodontitis, 
four with chronic periodontitis, and four subjects who have not experienced 
destructive periodontitis. Total RNA from 12 tissue samples were employed in 
order to generate genome wide transcriptome profiles. Data mining analysis, such 
as comparisons, gene ontology and pathway analyses were performed. 
Results: Comparison analysis revealed that 192 probes sets were 
differentially expressed between aggressive periodontitis subjects and healthy 
subjects, 43 when comparing chronic periodontitis and healthy, and 168 when 
comparing chronic periodontitis and aggressive periodontitis. Comparative gene 
ontological analysis identified 50 differentially regulated ontological groups in 
aggressive periodontitis subjects compared to healthy subjects, 27 in chronic 
periodontitis and healthy subjects, and 75 groups in chronic periodontitis and 
aggressive periodontitis. Genes with function in the immune system, including 
natural killer cells receptors, were most expressed in aggressive periodontitis; in 
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contrast, genes involved in proliferation and differentiation of keratinocytes, as well 
as genes with function in neural process were less expressed. Chronic 
periodontitis subjects were characterized by increased expression of genes related 
to response to external stimuli, and a decrease in the expression of genes related 
to the immune system. 
Conclusion: Microarray and data mining analysis demonstrate that 
chronic, and especially aggressive periodontitis presents differences in tissue gene 
expression profile between them and to healthy subjects, indicating that these 
diseases could present different pathways of periodontal destruction.  
Key words Periodontitis; Gene expression; Microarray; Susceptibility 
 
Introduction 
Periodontitis is one of the most common chronic inflammatory diseases, 
and is characterized by the destruction of periodontal tissue (Feng & Weinberg, 
2006). The attachment loss and bone destruction result from interactions between 
periodontal microorganisms and susceptible host, leading to the release of 
cytokines, chemokines and proteolytic enzymes that mediate tissue damage 
(Socransky & Haffajee, 2005). Epidemiologic studies suggest that up to 50% of the 
population is affected by chronic periodontitis while 1-15% may suffer from 
aggressive periodontitis (Demmer & Papapanou, 2010). 
Aggressive periodontitis are challenging pathological entity, once it is 
characterized by early onset, rapid attachment loss and bone destruction, and poor 
response to periodontal therapy, while chronic disease presents a slower 
progression, compatible with local factors (Armitage, 1999). In order to explain 
possible differences between both forms of disease, microbiological and host 
immune response aspects, as well as genetic aspects, have been studied. 
However, mechanisms responsible for these differences are poorly understood and 
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no conclusive results has been described yet (Armitage, 2010; Casarin et al., 2010; 
Stabholz et al., 2010; Dentino et al., 2013). Looking for a better understanding of 
the impact of host characteristics in pathologies development, a new tool to 
investigate pathological pathways has been used for identify possible alterations 
on periodontal disease, the gene profile investigation (Demmer et al., 2008; 
Danavian et al., 2012). 
To date, published studies investigating the gene expression profile in 
periodontitis have controversial results. Papapanou et al. (2004) reported no 
significant differences in gene expression at different pathological sites in patients 
with chronic and aggressive periodontitis, and limited differences between 
diseased and healthy sites. On the other hand, Kim et al. (2006), Demmer et al. 
(2008) and Danavian et al. (2012) showed a great number of genes that were 
differentially expressed in periodontitis compared to healthy sites. In addition, 
Beikler et al. (2008) demonstrated that in chronic periodontitis sites, the overall 
expression of immune and inflammatory genes was down-regulated following non-
surgical therapy.  
Despite researches investigating periodontitis gene expression profiles 
there is no conclusive results for chronic, and especially for aggressive 
periodontitis regarding the genes associated to periodontal destruction (Danavian 
et al., 2012). Perhaps this may be explained by the fact that most studies 
exclusively used healthy gingival tissues from individuals with periodontitis, which 
may not necessarily be identical to those healthy sites in subjects who have not 
experienced destructive periodontitis (Demmer et al., 2008), once gene expression 
is influenced due inherent or acquired characteristics (Krämer et al., 2013). 
Moreover, gene expression from healthy tissue reported in these studies may be 
influenced by subgingival microbiota (Papapanou et al., 2009; Kebschull & 
Papapanou, 2011). Thereby, the investigation of sites “free” of these variables, 
such as masticatory mucosa, could be an interesting form to identify intrinsic host 
alterations that could be associated to disease development and progression. 
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Therefore, the aim of the present study was to investigate the 
differences in gene expression profile of healthy masticatory mucosa in subjects 
with a history of generalized aggressive periodontitis, chronic periodontitis, and 
who not experienced destructive periodontitis. 
 
Material and Methods 
Subjects 
The study design was approved by the Ethics Committee of the 
University of Campinas (017/2010), and informed written consent was granted by 
each subject after explanations were provided. A total of twelve subjects were 
recruited from the patient referred to implant placement to the Graduate Clinic of 
Piracicaba Dental School, University of Campinas, Piracicaba, Brazil, between 
March 2011 and January 2012. Patients with a past of chronic periodontitis (n=4) 
or generalized aggressive periodontitis (n=4) (Armitage, 1999), and who had 
received regular periodontal maintenance care at least 1 year following active 
periodontal therapy, presenting full-mouth plaque index (Ainamo & Bay, 1975), and 
full-mouth bleeding score (Mühlemann & Son, 1971) less than 30% were selected. 
Another 4 subjects, with no history of periodontal disease (free of interproximal 
attachment loss and had no probing pocket depths of >4mm) were also enrolled 
(Sørensen et al., 2008; Jönsson et al., 2011). The participants were non-smokers, had 
not received systemic antibiotics or anti-inflammatory drugs in the previous 6 
months, did not have systemic diseases (e.g., cardiovascular, diabetes), and were 
not pregnant or lacting. The following clinical parameters were assessed in all 
participants before tissue collection: full-mouth plaque index, full-mouth bleeding 
score, probing pocket depth and clinical attachment level at six points around each 
tooth. 
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Biopsies 
Healthy masticatory mucosa tissue samples were obtained from 
edentulous sites at implant placement moment. After local anesthesia (Articain with 
1:100.000 epinephrine), performed distant from site of tissue collection in order to 
avoid possible effects on gene expression, two parallel linear incisions, 3 mm 
apart, were made through the soft tissue until bone contact was achieved. The two 
incisions were connected with perpendicular incisions delimiting a tissue sample of 
3 x 3 mm, which was carefully dissected (Donati et al., 2009). The tissue 
specimens comprised the oral epithelium and the underlying connective tissue. 
After collection, the specimens were rinsed with sterile saline solution, and 
immediately stored overnight in a RNA stabilization reagent (RNAlater, Ambion Inc, 
Austin, TX) at 4oC and then stored at -80oC for subsequent RNA isolation. 
 
Isolation of total RNA from tissue samples 
Tissue specimens were disrupted by a motor pestle (Marconi, 
Piracicaba, SP, Brazil) and homogenized in 1 ml of Trizol Reagent (Ambion Inc, 
Austin, TX, USA) for 5 minutes. After incubation with 200 µL of chloroform and 
centrifugation at 12,000 x g, RNA collected in the upper aqueous phase was 
precipitated by mixing with 500 µL isopropyl alcohol and additional centrifugation, 
and it was washed in 1mL of 75% ethanol. 
The remaining DNA was removed using RNase-Free DNase Kit (Turbo 
DNA-free, Ambion Inc, Austin, TX, USA) following the manufacturer’s instructions. 
RNA quantity was evaluated spectrophotometrically using a Nanodrop 2000 device 
(Thermo Scientific, Wilmington, DE, USA). Quality control of total RNA samples 
were determined prior to the microarray experiments using the RNA 6000 
NanoLabChip Kit of the Agilient 2100 Bioanalyzer (Agilent Technologies, Palo Alto, 
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CA, USA).  Samples that had RIN values above 8 were used for further microarray 
analysis.  
 
Double-stranded cDNA synthesis and purification 
Double-stranded cDNA was synthesized from five micrograms of total 
RNA using the cDNA Synthesis System (Roche Diagnostics, Mannheim, Germany) 
according to manufacturer’s instructions. cDNA samples were cleaned with 20 µl of 
T4 DNA Polymerase, 1,5 µl of RNase I, and 5 µl of proteinase K. Then, cDNA was 
purified using the High Pure PCR Product Purification Kit (Roche Diagnostics, 
Mannheim, Germany) according to the manufacturer’s instructions, with a final 
volume of 40 µl. 
 
Microarray hybridization 
Each cDNA sample was random-primer labeled with Cy3-nonamers 
according to Roche NimbleGen’s standard protocol using NimbleGen One-Color 
DNA Labeling Kits (Roche Diagnostics, Mannheim, Germany). Where possible, 
one microgram of cDNA was used in the labeling reaction. For those samples that 
did not yield one microgram of cDNA, the maximal volume (forty microliters) of the 
High Pure column-eluted cDNA was used. Using random assignment, each Cy3-
labeled cDNA sample was applied to NimbleGen Human Gene Expression 
12x135K Arrays (Roche Diagnostics, Mannheim, Germany). Each slide contains 
12 independent arrays, each with 135,000 probes covering 45,033 genes, 3 
probes/target gene. The array was then hybridized for 16 hours at 42°C, washed, 
dried, and scanned at 2 µm resolution using a NimbleGen MS 200 Microarray 
Scanner (Roche NimbleGen).  
 
Microarray data analysis 
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The NimbleScan v2.6 software (Roche NimbleGen) was used to extract 
fluorescence intensity signals from the scanned images. The data was analyzed 
using different packages in the software R. All packages were available in the 
Bioconductor open source software project for analysis of genomic data. 
Expression data were normalized and summarized using the Robust Multi-Array 
(RMA) analysis. 
Comparison analyses were then used to differentiate the real changes in 
gene expression levels between aggressive periodontitis group and healthy group 
(comparison I), chronic periodontitis group and healthy group (comparison II). Data 
were filtered to ensure both statistical and biological significance. Genes that 
showed at least two-fold changes in their gene expression and with adjusted p < 
0.05 (corrected for multiple testing using Benjamini-Hochberg method) were 
identified as differentially expressed (Koshi et al., 2007; Shimizu et al., 2010). 
Then, genes differentially expressed in both comparisons were again further 
assessed to determine gene expression levels between chronic periodontitis group 
and aggressive periodontitis group (comparison III). Gene ontology (GO) Biological 
Process analysis and pathway analysis based on the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database were used for further investigation on the 
differential genes of interest. Enrichment analysis of the data was then performed 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(Huang et al., 2009a; 2009b).  
 
Results 
Patients’ characteristics 
No differences were observed between groups regarding oral hygiene 
status (Full mouth plaque and bleeding indices). With regard to the clinical 
parameters the groups presented similar values of clinical attachment loss and 
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probing pocket depth. The mean age of aggressive periodontitis patients was 
32.25 ± 5.85 years, which was statistically younger than that of chronic 
periodontitis patients (51.75 ± 3.30 years old). However, there was no difference 
regarding the age between aggressive group and healthy group, and chronic group 
and healthy group (table 1).  
 
Microarray Analysis 
The microarray data (raw and normalized) were processed according to 
Minimum Information About a Microarray Experiment (MIAME) guidelines. Applying 
the cutoff criteria (corrected p value ≤ 0.05,  fold-change ≥ 2 or fold-change ≤ -2) 
transcriptome analysis revealed that 192 probes sets were differentially expressed 
between aggressive periodontitis group and healthy group (comparison I), 43 when 
comparing chronic periodontitis group and healthy group (comparison II), and 168 
when comparing chronic periodontitis group and aggressive periodontitis group 
(comparison III). The complete list of genes differentially regulated can be viewed 
in the supplementary tables 1, 2, and 3. 
 
Comparison I – Aggressive periodontitis group and Healthy group 
The microarray analysis in aggressive periodontitis group compared to 
healthy group showed that 56 transcripts were increased, and 136 were 
decreased. Fold-changes in expression ranged between 6.10 and 2.62 for the top 
15 probes sets, with increased expression, and between -6.36 to -3.10 for the top 
15 probes sets with decreased expression (table 2). Several constituents of natural 
killer cell, such as killer cell immunoglobulin-like receptors and killer cell lectin-like 
receptors, and other genes such as formyl peptide receptor 1 (FPR1), which are 
known to play an important role in regulation of the immune response were 
detected as up-regulated genes.  In contrast, genes involved in neural process, 
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such as internexin neuronal intermediate filament (INA); MAM domain containing 
glycosylphosphatidylinositol anchor 1 (MDGA1); semaphorin 7A (SEMA7A), and 
genes related to cellular growth, development and division, differentiation and 
cornification of keratinocytes, such as POU class 2 homeobox 3 (POU2F3), 
calmodulin-like 5 (CALML5), caspase 14, apoptosis-related cysteine peptidase 
(CASP14), early growth response 3 (EGR3), and DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 12 were found to be down-regulated.  
Gene ontological analysis identified 7 significantly and differentially up-
regulated ontological groups in aggressive periodontitis group compared to healthy 
group, including cellular defense response, immune response, immune system 
process, defense response, response to stimulus, and natural killer cell activation 
(table 3 for top GOs). In contrast, 43 groups, including neurotransmitter transport, 
nervous system development, development process, multicellular organismal 
development were found to be down-regulated. The complete list of gene ontology 
groups differentially expressed between aggressive periodontitis group and healthy 
group can be viewed in Supplementary table 4. Further, pathway analysis identified 
4 differentially expressed pathways: antigen processing and presentation, natural 
killer cell mediated cytotoxicity, graft-versus-host disease, and FC gamma R-
mediated phagocytosis (table 4).  
 
Comparison II – Chronic periodontitis group and Healthy group 
Comparing chronic periodontitis group and healthy group transcriptomes 
analysis revealed that 10 probes sets were up-regulated and 33 transcripts were 
down-regulated. Fold-changes in expression ranged between 4.8 and 2.03 for the 
10 probes sets with increased expression, and between -10.17 and -2.40 for the 
top 15 probes sets with decreased expression (table 5). Genes encoding proteins 
which mediate the presentation antigens - CD1b molecule (CD1B) and major 
histocompatibility complex, class II, DQ alpha 1 (HLA-DQA1), and genes related to 
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response to external stimulus and inflammation, such as kallikrein B plasma 
(Fletcher factor) 1 (KLKB1), and neuropeptide Y (NPY), were detected as up-
regulated. Lipopolysaccharide binding protein (LBP), selectin E (SELE), Toll-like 
receptor 8 (TLR8), integrin-binding sialoprotein (IBSP) major structural of the bone 
matrix, and ubiquitously transcribed tetratricopeptide repeat gene (UTY) involved in 
oxireductase activity,  were found to be down-regulated.  
Gene ontology analysis identified 3 up-regulated ontological groups: 
regulation of proteolysis, antigen processing and presentation, and regulation of 
multicellular organismal process. In contrast, 24 ontological groups, including 
defense response, immune system processes, and response to wounding, were 
found to be down-regulated (table 6 for top GOs). The complete list of gene 
ontology groups differentially expressed between chronic periodontitis group and 
healthy group can be viewed in Supplementary table 5. Pathway analysis reveals 
that cell adhesion molecules pathway was differentially expressed.  
 
Comparison III – Chronic periodontitis group and Aggressive 
periodontitis group 
Comparison III showed that 74 probes sets were higher expressed and 
94 were lower expressed in chronic periodontitis group compared to aggressive 
periodontitis group. Fold-changes in expression ranged between 7.27 and 3.05 for 
the top 15 probes sets, with increased expression, and between -4.3 and -2.90 for 
the top 15 probes sets with decreased expression (table 7). Genes for epithelial 
components and differentiation, including psoriasis susceptibility 1 (PSORS1C1), 
caspase 14 (CASP14), and genes involved in lymphocyte development, 
endothelial cell growth and migration (early growth response 3 - EGR3) were found 
to be higher expressed. On the other hand, genes encoding interleukin-6 (IL6), 
interleukin-1β (IL1B), selectin E (SELE), and toll-like receptor 8 (TLR8) were 
detected as lower expressed genes.  
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Gene ontology analysis identified 19 differentially higher expressed 
groups, including epidermis and ectoderm development, tissue development, 
phospholipid catabolic process, and leukotriene metabolic process. In contrast, 56 
groups were lower expressed, including immune response, immune system 
process, inflammatory response (table 8 for top GOs). The complete list of gene 
ontology groups differentially expressed between chronic periodontitis group and 
aggressive periodontitis group can be viewed in Supplementary table 4 Further, 
pathway analysis identified 6 differentially expressed pathways, including 
arachidonic acid metabolism, Fc gamma R-mediated phagocytosis and Toll-like 
receptor signaling pathway (table 4).  
 
Discussion 
The present study describe the gene expression profiles of healthy 
masticatory mucosa in subjects with a past history of chronic periodontitis and 
generalized aggressive periodontitis using microarray analyses, including 
comparisons, gene ontology and pathway analysis. The primary aim of this study 
was assess and identify differences in gene expression between chronic and 
aggressive periodontitis. Thereby, we enrolled subjects who have not experienced 
destructive periodontitis, as demonstrated by clinical periodontal data and intraoral 
radiographs, to control molecular events without disease revelance, once 
transcriptomes of healthy gingival tissues of individuals who have not experienced 
periodontitis may be different those of subjects with periodontitis (Demmer et al., 
2008; Becker et al., 2012). Another important point is the employment of healthy 
masticatory mucosa for microarray analysis, instead healthy gingival tissue 
adjacent to teeth, aiming eliminates the influence of the subgingival microbiota in 
gene expression of gingival tissues (Papapanou et al., 2009). 
Our findings demonstrate significant differences in gene expression 
between healthy masticatory mucosa of subjects in aggressive periodontitis group 
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versus healthy group, chronic periodontitis in comparison to healthy group, and, 
especially between chronic periodontitis group and aggressive periodontitis group. 
This report does not include an in-depth discussion of specific differentially 
regulated pathways in groups assessed but rather provides examples, for a few 
genes with altered expression that could be associated to disease development 
and progression, which underscore the usefulness of the expression data. 
Comparing gene expression in aggressive periodontitis group to healthy 
group, through the top genes, gene ontology groups and pathway analysis, natural 
killer cell related genes (killer cell immunoglobulin-like receptors and killer cell 
lectin-like receptors) were the major genes up-regulated. Natural killer (NK) cells 
are cytotoxic lineage of lymphocytes that can mediate lysis of certain tumor cells 
and virus-infected cells without previous activation. They can also regulate specific 
humoral and cell-mediated immunity. Recent studies have demonstrated the 
relationship between natural killer cells and inflamed gingival tissues, and 
aggressive periodontitis (Krämer et al., 2013; Muthukuru, 2012). In a recent study 
Krämer et al. (2013) reported significant induction of the NK cell mediated 
cytotoxicity, mainly by overexpression of CD2-like receptor activating cytotoxic 
cells (CRACC), in aggressive periodontitis lesions when compared to tissues from 
chronic periodontitis lesions. Jönsson et al. (2011) reported that multiple genes 
associated with natural killer (NK) cell function, including killer cell lectin-like 
receptors, were differentially regulated during induction of experimental gingivitis. 
They are of particular interest as NK cells represent a link between a bacterially 
induced immune response and an auto-immune component that has been 
suggested to play a role in the pathobiology of periodontitis (Yamazaki et al., 
2001). 
Gene ontology enrichment analyses among down-regulated genes in 
aggressive periodontitis group vs. healthy group demonstrated that most of these 
genes were involved in neural process. Interestingly, Offenbacher et al. (2009) 
reported that genes and pathways associated with transmission of nerve impulses, 
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nerve development, and maturation were moderately up-regulated in induction 
phase of experimental gingivitis. These genes were linked broadly to epithelial 
tissues, vasculature, and wound healing, representing a novel and unanticipated 
finding for gingivitis (Offenbacher et al., 2009). On the other hand, the activation of 
neural pathways does not appear to represent a dominant transcriptome pathway 
in periodontitis (Demmer et al., 2008). Despite these contradictory results, our work 
suggests that the role of neural process in tissue homeostasis, and inflammation, 
requires future investigation for clarify its role on periodontal disease. 
Genes involved in proliferation, differentiation and cornification of 
keratinocytes were down-regulated in aggressive periodontitis, both in comparison 
1 as comparison 3 (up-regulated in chronic group or, alternatively, least expressed 
in aggressive group). Recent microarray studies of disease gingival tissues have 
also reported decreased gene expression of epithelial components. Desmocollin 1, 
member of cadherin superfamily of Ca2+ dependent cell adhesion molecules, were 
found to be least expressed in diseased gingival tissue, and in refractory 
periodontitis (Kim et al., 2006; Demmer et al., 2008). Similarly Abe et al. (2011) 
found that genes for epithelial constructive and cytoskeletal proteins, including 
keratins, epiplakins and dermokines, were found to be down-regulated in 
periodontitis-affected gingival tissues. 
In comparison II genes with biological function in proteolysis and 
regulation of multicellular organismal process, among them kallikrein B 1 and 
neuropeptide Y, were found as up-regulated. Kallikrein is glycoprotein that 
participates in the surface-dependent activation of blood coagulation, fibrinolysis, 
kinin generation and inflammation. It was involved in the inflammatory response to 
Porphyromonas gingivalis triggering bradykinin production (Rapala-Kozik et al., 
2011). Bradykinin are powerful proinflammatory mediators, and they have been 
implicated in the pathogenesis of periodontitis due to their potential to strongly 
upregulate bone resorption (Brechter et al., 2008). 
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An unexpected result was overexpression in chronic periodontitis of 
gene encoding neuropeptide Y (NPY). There is some evidence that NPY is 
involved in pathogenesis of periodontal disease, with inhibitory effects on immune 
mechanisms (Del Rey et al., 1981), and protective bone metabolism (Haug & 
Heyeraas, 2006). Indeed Lundy et al. (2009) found higher levels of NPY in healthy 
sites compared to periodontitis sites. On the other hand, severe or prolonged 
neurogenic inflammation may result in the inflammatory response mediating injury 
rather than facilitating repair, as normally occurs (Lundy & Linden, 2004). 
Moreover, NPY is involved in a shift in the ratio of T-helper 1 to T-helper 2 cells 
(Bedoui et al., 2003), which is a characteristic of chronic periodontitis.  
Lipopolysaccharide binding protein (LBP), selectin E, and Toll-like 
receptor 8 (TLR-8) encoding genes overlapped with the most gene ontology 
groups down-regulated in chronic periodontitis group compared to healthy group. 
Interestingly, selectin E and TLR-8 also were down-regulated in comparison III. 
The protein encoded by lipopolysaccharide binding protein (LPB) gene is involved 
in the acute-phase immunologic response to gram-negative bacterial infections, 
possibly to prevent exaggerated responses to LPS (Thompson & Kitchens, 2006). 
Studies have indicated that LBP may be involved in the initiation and development 
of periodontal disease (Wang & Ohura, 2002). Indeed, Ren et al. (2009) reported 
that LBP suppressed interleukin-1β (IL-1β) expression induced by LPS in human 
gingival fibroblasts. However, there is evidence that depending on the 
concentrations of LBP and can be both enabling and inhibiting cellular response to 
LPS, with higher concentrations of LPB inhibiting pro-inflammatory cytokine 
production (TNF-α) (Amura et al., 1997). Therefore, lower expression of LBP gene 
in chronic periodontitis patients may impair the immune-inflammatory response to 
periodontopathogens, contributing to initiation and progression of periodontal 
disease.  
Other gene lesser expressed in chronic periodontitis was toll-like 
receptor 8 (TLR-8). Toll-like receptors plays a fundamental role in pathogen 
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recognition and activation of innate immunity. They recognize pathogen-associated 
molecular patterns (PAMPs) that are expressed on infectious agents, and mediate 
the production of cytokines necessary for the development of effective immunity. 
TLR-8, as TLR-3, TLR-7, and TLR-9, recognizes viral and/or bacterial nucleic acid 
(Mahanonda & Pichyangkul, 2007). There is only one study that evaluated the 
expression and distribution of TLR-8 in periodontitis, by immunohistochemistry, 
that reported that TLR-8 was found to be expressed by epithelial cells at similar 
frequency in healthy and in periodontitis, while in the connective tissue percentage 
of TLR-8 was significantly higher in periodontal gingival samples than healthy 
tissue (Beklen et al., 2008). More studies are needed to better understanding of the 
role of TLR-8 in the pathogenesis of periodontal disease. May be speculate that a 
lower expression in this receptor could contribute to development of periodontal 
disease, for change innate immunity to periodontopathogens.  
Additionally, the microarray analysis displays a distinct gene expression 
profile between chronic periodontitis and aggressive periodontitis. Interestingly, 
immune system process, response to wounding, cell adhesion, and biological 
adhesion gene ontology group was down-regulated in chronic periodontitis group 
both in this comparison as compared to healthy group. Similarly, in aggressive 
periodontitis immune system process and immune response was up-regulated in 
this comparison (least expressed in chronic periodontitis, or alternatively, most 
expressed in aggressive periodontitis) and in comparison I (aggressive 
periodontitis group and healthy group). These findings highlight the importance of 
these groups in chronic and aggressive periodontitis, further corroborating the idea 
that the chronic and aggressive periodontitis may have distinct pathobiology.  
Interestingly pro-inflammatory cytokines interleukin-1β (IL-1β) and 
interleukin-6 (IL-6) were most expressed in aggressive periodontitis than chronic 
periodontitis. Similar to our report, several studies have demonstrated that 
generalized aggressive periodontitis subjects appear to have a hyper-inflammatory 
response that may increase host susceptibility to tissue destruction. Duarte et al. 
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(2010) reported elevated serum levels of TNF-α in subjects with generalized 
aggressive periodontitis compared to periodontal healthy subjects at 6 months 
post-therapy. Moreover, Bastos et al. (2009) evaluated TNF-α and interleukin-4 (IL-
4) levels in GCF from generalized aggressive periodontitis and healthy subjects 
(control sites); they reported that healthy and diseased sites from aggressive 
periodontitis presented high levels of pro-inflammatory cytokine TNF-α when 
compared to healthy subjects, while the concentration of anti-inflammatory cytokine 
IL-4 was lower in aggressive periodontitis than healthy subjects.  
We believe that these genes play an important role in the tissue 
homeostasis and/or periodontal disease susceptibility. However, it should be 
pointed out that the results of this study are limited, because there were relatively 
low number of specimens, which warrants caution in interpretation and 
generalizability. Therefore the presented gene expression data need to be 
subjected to confirmatory steps, such polymerase chain reaction (PCR) methods 
for confirmation on the mRNA level, and by proteomic analyses. 
In conclusion, we demonstrate differences in gene expression profile of 
healthy masticatory mucosa in chronic periodontitis, and particularly in aggressive 
periodontitis, when compared among them and with healthy group, whose could be 
associated to differences in the pathogenesis between them.   
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Table 1. Patient characteristics. 
Characteristics Aggressive Chronic Healthy p-value 
Age (mean±sd) 32.25 ± 5.85 A 51.75 ± 3.30 B 46.25 ± 11.44 AB 0.0153 
FMPI (mean±sd) 23.10 ± 6.53 A 17.05 ± 8.42 A  19.36 ± 5.38 A 0.2696 
FMBS (mean±sd) 24.83 ± 9.05 A 23.53 ± 7.69 A 19.39 ± 2.31 A 0.5428 
PPD (mean±sd) 2.35 ± 0.05 A 2.28 ± 0.27 A 2.13 ± 0.23 A 0.3504 
CAL (mean±sd) 5.44 ± 1.04 A 5.44 ± 0.90 A 5.15 ± 0.72 A 0.8729 
Diferente letters (capital for intergroup analysis) indicate statistical difference by one-
way ANOVA / Tukey test 
Sd – Standard Deviation; FMPI – Full Mouth Plaque Index; FMBS – Full Mouth Bleeding Index; PPD 
– Probing Pocket Depth; CAL – Clinical Attachment Level. 
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Table 2. Top differentially expressed genes in aggressive periodontitis group relative to healthy 
group. 
Gene Symbol Gene Name FC p 
Up-Regulated     
SLC35F3 solute carrier family 35, member F3 6.10 0.005 
LOC554223 hypothetical LOC554223 3.57 0.038 
MUC16 mucin 16, cell surface associated 3.52 0.029 
KIR2DL4 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 3.22 0.016 
KIR3DL1 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 3.14 0.012 
KLRC1 killer cell lectin-like receptor subfamily C, member 1 3.08 0.029 
KIR2DS5 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5 3.07 0.015 
KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 2.90 0.022 
EDN2 endothelin 2 2.80 0.027 
KIR2DL5A killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5A 2.76 0.018 
KLRC4 killer cell lectin-like receptor subfamily C, member 4 2.75 0.017 
KIR2DS2 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 2.70 0.012 
KLRC3 killer cell lectin-like receptor subfamily C, member 3 2.67 0.011 
SH2D1B SH2 domain containing 1B 2.64 0.005 
N/A Homo sapiens cDNA FLJ46698 fis, clone TRACH3013684. 2.62 0.031 
Down-Regulated     
EGR3 early growth response 3 -6.36 0.002 
ZFY zinc finger protein, Y-linked -6.33 0.036 
CYorf15A chromosome Y open reading frame 15A -5.25 0.043 
LOC284116 hypothetical protein LOC284116 -4.89 0.001 
SMPD3 
sphingomyelin phosphodiesterase 3, neutral membrane (neutral 
sphingomyelinase II) 
-4.81 0.003 
CYorf15B chromosome Y open reading frame 15B -4.30 0.031 
NLGN4Y neuroligin 4, Y-linked -3.98 0.014 
KCNJ12 potassium inwardly-rectifying channel, subfamily J, member 12 -3.90 0.001 
CASP14 caspase 14, apoptosis-related cysteine peptidase -3.87 0.032 
ECHDC3 enoyl Coenzyme A hydratase domain containing 3 -3.71 0.011 
RPS4Y1 ribosomal protein S4, Y-linked 1 -3.46 0.050 
HAL histidine ammonia-lyase -3.42 0.019 
SLITRK5 SLIT and NTRK-like family, member 5 -3.29 0.025 
HTR3A 5-hydroxytryptamine (serotonin) receptor 3A -3.16 0.026 
ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide -3.10 0.016 
 
     
FC – Fold Change - describes the ratio of mean expression levels in aggressive periodontitis 
groups over the mean expression levels in healthy group. Multiple probe sets map to a single gene.  
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Table 3. Top Gene Ontology Groups differentially expressed in aggressive periodontitis group 
relative to healthy group. 
Group Name ID p-value Count 
% 
regulated 
Up-Regulated         
Cellular defense response GO:0006968 2,3E-7 6 12,8 
Response to stimulus GO:0050896 3,3E-5 20 42,6 
Defense response GO:0006952 5,2E-5 9 19,1 
Immune response GO:0006955 1,2E-4 9 19,1 
Immune system process GO:0002376 2,7E-4 10 21,3 
Response to stress GO:0006950 3,1E-2 9 19,1 
Natural killer cell activation GO:0030101 4,7E-2 2 4,3 
Down-Regulated         
Neurotransmitter transport GO:0006836 2,2E-5 7 5,6 
Secretion GO:0046903 1,1E-3 9 7,2 
Nervous system development GO:0007399 1,1E-3 18 14,4 
Developmental process GO:0032502 2,8E-3 35 28,0 
Generation of a signal involved in cell-cell 
signaling GO:0003001 
2,8E-3 5 4,0 
Transmission of nerve impulse GO:0019226 2,8E-3 9 7,2 
Secretion by cell GO:0032940 3,0E-3 7 5,6 
Synaptic transmission GO:0007268 4,4E-3 8 6,4 
Multicellular organismal development GO:0007275 4,5E-3 32 25,6 
Anatomical structure development GO:0048856 5,3E-3 29 23,2 
 
Count – gene involved in the GO term. 
% regulated – percentage of genes involved in given term (number of genes involved in given term 
divided by the total number of input gene). 
 
 
 
 
 
 
  
48 
 
Table 4. Differentially expressed pathways, determined by pathway analysis 
Pathways p-value Counts 
Comparison I - Aggressive periodontitis vs Healthy     
Antigen processing and presentation 2,3E-13 15 
Natural killer cell mediated cytotoxicity 2,4E-8 13 
Graft-versus-host disease 2,3E-7 8 
Fc gamma R-mediated phagocytosis 9,7E-2 4 
Comparison II - Chronic periodontitis vs Healthy     
Cell adhesion molecules (CAMs) 5,6E-2 3 
Comparison III - Chronic vs Aggressive periodontitis     
Hematopoietic cell lineage 1,4E-3 6 
Fc gamma R-mediated phagocytosis 1,4E-2 5 
Arachidonic acid metabolism 1,7E-2 4 
Cell adhesion molecules (CAMs) 4,0E-2 5 
ECM-receptor interaction 4,9E-2 4 
Toll-like receptor signaling pathway 7,6E-2 4 
Counts – gene counts included in the Kyoto Encyclopedia of Genes and Genomes pathway. 
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Table 5. Top differentially expressed genes in chronic periodontitis group relative to healthy group. 
Gene 
Symbol Gene Name FC p 
Up-Regulated     
HS3ST4 heparan sulfate (glucosamine) 3-O-sulfotransferase 4 4.80 0.019 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 3.46 0.046 
KLKB1 kallikrein B, plasma (Fletcher factor) 1 2.55 0.050 
CD1B CD1b molecule 2.43 0.005 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 2.33 0.027 
SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 2.23 0.029 
NPTX2 neuronal pentraxin II 2.12 0.011 
NPTX2 neuronal pentraxin II 2.12 0.027 
NPY neuropeptide Y 2.03 0.040 
C1D nuclear DNA-binding protein 2.03 0.031 
Down-Regulated     
DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked -10.17 0.050 
IBSP integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II) -5.76 0.048 
CYorf15A chromosome Y open reading frame 15A -5.39 0.041 
CYorf14 chromosome Y open reading frame 14 -4.63 0.043 
DDX43 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 -4.50 0.012 
CYorf15B chromosome Y open reading frame 15B -4.46 0.028 
NLGN4Y neuroligin 4, Y-linked -4.11 0.013 
GLT1D1 glycosyltransferase 1 domain containing 1 -3.10 0.007 
SELE selectin E (endothelial adhesion molecule 1) -2.87 0.049 
LILRA1 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 -2.68 0.016 
UTY ubiquitously transcribed tetratricopeptide repeat gene, Y-linked -2.68 0.046 
ZNF533 zinc finger protein 533 -2.61 0.041 
NGFB nerve growth factor, beta polypeptide -2.54 0.034 
FCN1 ficolin (collagen/fibrinogen domain containing) 1 -2.52 0.030 
N/A Homo sapiens cDNA FLJ14320 fis, clone PLACE3000455. -2.40 0.016 
 
FC – Fold Change - describes the ratio of mean expression levels in chronic periodontitis groups 
over the mean expression levels in healthy group. Multiple probe sets map to a single gene.  
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Table 6. Top Gene Ontology Groups differentially expressed in chronic periodontitis group relative 
to healthy group. 
Group Name ID p-value Count % regulated 
Up-Regulated         
Regulation of proteolysis GO:0030162 3,0E-2 2 22,2 
Antigen processing and presentation GO:0019882 4,6E-2 2 22,2 
Regulation of response to external stimulus GO:0032101 8,7E-2 2 22,2 
Down-Regulated         
Defense response GO:0006952 1,4E-3 6 20,0 
Immune system process GO:0002376 2,0E-3 7 23,3 
Multi-organism process GO:0051704 2,2E-3 6 20,0 
Cell adhesion GO:0007155 2,5E-3 6 20,0 
Biological adhesion GO:0022610 2,5E-3 6 20,0 
Response to lipopolysaccharide GO:0032496 5,2E-3 3 10,0 
Response to wounding GO:0009611 5,9E-3 5 16,7 
Response to stress GO:0006950 6,5E-3 8 26,7 
Response to molecule of bacterial origin GO:0002237 6,5E-3 3 10,0 
Response to other organism GO:0051707 7,6E-3 4 13,3 
Count – gene involved in the GO term. 
% regulated – percentage of genes involved in given term (number of genes involved in given term 
divided by the total number of input gene). 
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Table 7. Top differentially expressed genes in chronic periodontitis group relative to aggressive 
periodontitis group. 
Gene 
Symbol Gene Name FC p 
Up-Regulated     
PSORS1C1 psoriasis susceptibility 1 candidate 1 7.27 0.009 
EGR3 early growth response 3 6.29 0.002 
ECHDC3 enoyl Coenzyme A hydratase domain containing 3 4.51 0.004 
CASP14 caspase 14, apoptosis-related cysteine peptidase 4.16 0.026 
KCNJ12 potassium inwardly-rectifying channel, subfamily J, member 12 4.09 0.001 
LOC284116 hypothetical protein LOC284116 3.87 0.003 
CCDC85B coiled-coil domain containing 85B 3.82 0.028 
ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide 3.64 0.008 
FLJ16165 FLJ16165 protein 3.64 0.025 
SMPD3 
sphingomyelin phosphodiesterase 3, neutral membrane (neutral 
sphingomyelinase II) 3.54 0.010 
HAL histidine ammonia-lyase 3.54 0.016 
HTR3A 5-hydroxytryptamine (serotonin) receptor 3A 3.46 0.018 
KLK9 kallikrein 9 3.41 0.002 
PNPLA1 patatin-like phospholipase domain containing 1 3.21 0.046 
SPRR4 small proline rich protein 4 3.05 0.045 
Down-Regulated     
SLC35F3 solute carrier family 35, member F3 -4.3 0.042 
SELE selectin E (endothelial adhesion molecule 1) -3.9 0.039 
IL6 interleukin 6 (interferon, beta 2) -3.8 0.030 
LILRA5 
leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 
5 -3.7 0.014 
FPRL1 formyl peptide receptor-like 1 -3.5 0.013 
LOC554223 hypothetical LOC554223 -3.5 0.034 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) -3.4 0.002 
LOC440607 Fc-gamma receptor I B2 -3.3 0.004 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 -3.3 0.009 
CCL23 chemokine (C-C motif) ligand 23 -3 0.034 
LYSMD1 LysM, putative peptidoglycan-binding, domain containing 1 -3 0.008 
PSCA prostate stem cell antigen -3 0.046 
N/A Homo sapiens cDNA FLJ14320 fis, clone PLACE3000455. -3 0.004 
KLRF1 killer cell lectin-like receptor subfamily F, member 1 -2.9 0.012 
ELOVL2 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 -2.9 0.048 
FC – Fold Change - describes the ratio of mean expression levels in chronic periodontitis groups 
over the mean expression levels in aggressive periodontitis group. Multiple probe sets map to a 
single gene.  
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Table 8. Top Gene Ontology Groups differentially expressed in chronic periodontitis group relative 
to aggressive periodontitis. 
Group Name ID p-value Count % regulated 
Up-Regulated         
Phospholipid catabolic process GO:0009395 3,4E-3 3 4,3 
Leukotriene metabolic process GO:0006691 3,4E-3 3 4,3 
Cellular alkene metabolic process GO:0043449 3,7E-3 3 4,3 
Lipid catabolic process GO:0016042 4,9E-3 5 7,1 
Epidermis development GO:0008544 6,1E-3 5 7,1 
Ectoderm development GO:0007398 7,9E-3 5 7,1 
Icosanoid metabolic process GO:0006690 1,5E-2 3 4,3 
Unsaturated fatty acid metabolic process GO:0033559 1,7E-2 3 4,3 
Cellular lipid metabolic process GO:0044255 1,7E-2 7 10,0 
Ion transport GO:0006811 3,1E-2 8 11,4 
Down-Regulated         
Immune response GO:0006955 5,0E-6 14 16,7 
Immune system process GO:0002376 1,3E-5 16 19,0 
Cell adhesion GO:0007155 3,1E-5 13 15,5 
Biological adhesion GO:0022610 3,2E-5 13 15,5 
Inflammatory response GO:0006954 6,5E-5 9 10,7 
Response to wounding GO:0009611 7,1E-5 11 13,1 
Defense response GO:0006952 2,4E-4 11 13,1 
Locomotion GO:0040011 4,5E-4 9 10,7 
Cell-cell adhesion GO:0016337 1,1E-3 7 8,3 
Response to external stimulus GO:0009605 1,4E-3 12 14,3 
Count – gene involved in the GO term. 
% regulated – percentage of genes involved in given term (number of genes involved in given term 
divided by the total number of input gene). 
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Supplementary table 1. Differentially expressed genes in aggressive periodontitis group relative to 
healthy group. 
Gene Symbol Gene Name FC p 
Up-Regulated     
SLC35F3 solute carrier family 35, member F3 6.10 0.005 
LOC554223 hypothetical LOC554223 3.57 0.038 
MUC16 mucin 16, cell surface associated 3.52 0.029 
KIR2DL4 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 3.22 0.016 
KIR3DL1 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 3.14 0.012 
KLRC1 killer cell lectin-like receptor subfamily C, member 1 3.08 0.029 
KIR2DS5 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5 3.07 0.015 
KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 2.90 0.022 
EDN2 endothelin 2 2.80 0.027 
KIR2DL5A killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5A 2.76 0.018 
KLRC4 killer cell lectin-like receptor subfamily C, member 4 2.75 0.017 
KIR2DS2 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 2.70 0.012 
KLRC3 killer cell lectin-like receptor subfamily C, member 3 2.67 0.011 
SH2D1B SH2 domain containing 1B 2.64 0.005 
N/A Homo sapiens cDNA FLJ46698 fis, clone TRACH3013684. 2.62 0.031 
PLGLA1 plasminogen-like A1 2.62 0.045 
KIR2DL1 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1 2.62 0.020 
KLRC2 killer cell lectin-like receptor subfamily C, member 2 2.59 0.021 
LOC653489 
similar to Ran-binding protein 2 (RanBP2) (Nuclear pore complex protein Nup358) 
(Nucleoporin Nup358) (358 kDa nucleoporin) (P270) 
2.59 0.041 
KIR2DS4 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 4 2.57 0.010 
RGPD4 RANBP2-like and GRIP domain containing 4 2.56 0.049 
TXLNB taxilin beta 2.52 0.015 
KIR3DL2 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 2.52 0.031 
KLHL4 kelch-like 4 (Drosophila) 2.48 0.003 
N/A Homo sapiens clone KIR2DS2v2 killer-cell Ig-like receptor mRNA, complete cds. 2.45 0.007 
LQK1 LQK1 hypothetical protein short isoform 2.44 0.031 
CLDN8 claudin 8 2.42 0.022 
KIR2DS1 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1 2.36 0.010 
KIR2DL2 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2 2.34 0.014 
IL18RAP interleukin 18 receptor accessory protein 2.34 0.033 
LOC646299 hypothetical protein LOC646299 2.33 0.002 
C12orf54 chromosome 12 open reading frame 54 2.31 0.001 
KIR3DL3 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 3 2.31 0.020 
INSL3 insulin-like 3 (Leydig cell) 2.31 0.029 
C13orf18 chromosome 13 open reading frame 18 2.30 0.035 
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HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 2.30 0.050 
FLJ26175 FLJ26175 protein 2.29 0.004 
WDR49 WD repeat domain 49 2.29 0.010 
KIR2DS3 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 3 2.27 0.001 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 2.25 0.023 
N/A Homo sapiens clone FLB7723 PRO2055 mRNA, complete cds. 2.21 0.030 
FHAD1 forkhead-associated (FHA) phosphopeptide binding domain 1 2.17 0.007 
LOC440895 similar to LIM and senescent cell antigen-like domains 3 2.17 0.029 
PENK proenkephalin 2.14 0.035 
PDE4D 
phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, 
Drosophila) 
2.13 0.024 
C2orf27 chromosome 2 open reading frame 27 2.13 0.029 
C1D nuclear DNA-binding protein 2.13 0.028 
KLRD1 killer cell lectin-like receptor subfamily D, member 1 2.10 0.026 
OR1N2 olfactory receptor, family 1, subfamily N, member 2 2.09 0.022 
LOC644246 hypothetical protein LOC644246 2.09 0.039 
NPTX2 neuronal pentraxin II 2.08 0.028 
FPR1 formyl peptide receptor 1 2.07 0.016 
NNMT nicotinamide N-methyltransferase 2.07 0.039 
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 2.06 0.013 
AADACL1 arylacetamide deacetylase-like 1 2.04 0.015 
TTLL9 tubulin tyrosine ligase-like family, member 9 2.03 0.009 
Down-Regulated     
EGR3 early growth response 3 -6.36 0.002 
ZFY zinc finger protein, Y-linked -6.33 0.036 
CYorf15A chromosome Y open reading frame 15A -5.25 0.043 
LOC284116 hypothetical protein LOC284116 -4.89 0.001 
SMPD3 
sphingomyelin phosphodiesterase 3, neutral membrane (neutral 
sphingomyelinase II) 
-4.81 0.003 
CYorf15B chromosome Y open reading frame 15B -4.30 0.031 
NLGN4Y neuroligin 4, Y-linked -3.98 0.014 
KCNJ12 potassium inwardly-rectifying channel, subfamily J, member 12 -3.90 0.001 
CASP14 caspase 14, apoptosis-related cysteine peptidase -3.87 0.032 
ECHDC3 enoyl Coenzyme A hydratase domain containing 3 -3.71 0.011 
RPS4Y1 ribosomal protein S4, Y-linked 1 -3.46 0.050 
HAL histidine ammonia-lyase -3.42 0.019 
SLITRK5 SLIT and NTRK-like family, member 5 -3.29 0.025 
HTR3A 5-hydroxytryptamine (serotonin) receptor 3A -3.16 0.026 
ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide -3.10 0.016 
SIM2 single-minded homolog 2 (Drosophila) -3.05 0.043 
EDN3 endothelin 3 -3.02 0.044 
  
55 
 
KLK9 kallikrein 9 -2.89 0.005 
SNRP70 small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen) -2.88 0.004 
HRH3 histamine receptor H3 -2.84 0.017 
N/A Homo sapiens cDNA clone MGC:88155 IMAGE:30417356, complete cds. -2.84 0.043 
LOC644193 similar to Y51B11A.1 -2.84 0.008 
LOC441161 hypothetical LOC441161 -2.83 0.007 
DLX2 distal-less homeobox 2 -2.80 0.007 
UTY ubiquitously transcribed tetratricopeptide repeat gene, Y-linked -2.79 0.039 
KIAA1545 KIAA1545 protein -2.74 0.006 
FAM83G family with sequence similarity 83, member G -2.73 0.002 
N/A Homo sapiens cDNA FLJ44636 fis, clone BRACE2025452. -2.73 0.005 
PAX8 paired box gene 8 -2.72 0.003 
JMJD2B jumonji domain containing 2B -2.69 0.003 
COMP cartilage oligomeric matrix protein -2.65 0.038 
NTNG1 netrin G1 -2.64 0.022 
FLJ45455 FLJ45455 protein -2.64 0.015 
LOC283174 hypothetical protein LOC283174 -2.63 0.011 
SERPINB7 serpin peptidase inhibitor, clade B (ovalbumin), member 7 -2.63 0.025 
TRPV3 transient receptor potential cation channel, subfamily V, member 3 -2.62 0.020 
FBS1 fibrosin 1 -2.59 0.009 
RP13-
297E16.1 
DNA segment on chromosome X and Y (unique) 155 expressed sequence, isoform 
1 
-2.57 0.006 
PLA2G4E phospholipase A2, group IVE -2.56 0.010 
DKK2 dickkopf homolog 2 (Xenopus laevis) -2.54 0.005 
SLC6A11 solute carrier family 6 (neurotransmitter transporter, GABA), member 11 -2.51 0.005 
C1orf170 chromosome 1 open reading frame 170 -2.51 0.029 
IQSEC1 IQ motif and Sec7 domain 1 -2.50 0.009 
PSG2 pregnancy specific beta-1-glycoprotein 2 -2.50 0.043 
CBX4 chromobox homolog 4 (Pc class homolog, Drosophila) -2.49 0.003 
LOC339240 keratin pseudogene -2.48 0.017 
CALML5 calmodulin-like 5 -2.48 0.009 
SEMA7A semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group) -2.47 0.002 
FLJ90166 hypothetical protein FLJ90166 -2.47 0.033 
POU2F3 POU domain, class 2, transcription factor 3 -2.47 0.002 
SERPINB12 serpin peptidase inhibitor, clade B (ovalbumin), member 12 -2.46 0.028 
RIMS3 regulating synaptic membrane exocytosis 3 -2.45 0.034 
LOC284837 hypothetical protein LOC284837 -2.43 0.001 
EGR3 early growth response 3 -2.42 0.010 
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 -2.40 0.001 
N/A Homo sapiens cDNA FLJ43768 fis, clone TESTI2049422. -2.39 0.002 
CENTB5 centaurin, beta 5 -2.39 0.001 
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ERBB2 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian) 
-2.39 0.010 
CYP26B1 cytochrome P450, family 26, subfamily B, polypeptide 1 -2.34 0.007 
C1orf34 chromosome 1 open reading frame 34 -2.34 0.024 
PSG9 pregnancy specific beta-1-glycoprotein 9 -2.34 0.049 
PVRL1 poliovirus receptor-related 1 (herpesvirus entry mediator C -2.33 0.040 
TCEB3C transcription elongation factor B polypeptide 3C (elongin A3) -2.33 0.002 
IRX6 iroquois homeobox protein 6 -2.33 0.042 
N/A 
Homo sapiens sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6C, mRNA (cDNA clone MGC:138675 IMAGE:40036286), 
complete cds. 
-2.31 0.002 
BAI1 brain-specific angiogenesis inhibitor 1 -2.30 0.012 
RP5-1119A7.4 hypothetical protein FLJ23322 -2.29 0.001 
DNM1 dynamin 1 -2.29 0.000 
ZBTB7B zinc finger and BTB domain containing 7B -2.26 0.008 
LOC654433 hypothetical LOC654433 -2.26 0.042 
FLJ13137 hypothetical gene supported by AK125122 -2.25 0.011 
CRMP1 collapsin response mediator protein 1 -2.24 0.032 
PPFIA3 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting 
protein (liprin), alpha 3 
-2.24 0.006 
DEGS2 degenerative spermatocyte homolog 2, lipid desaturase (Drosophila) -2.23 0.049 
LOC646182 similar to XG glycoprotein precursor (Protein PBDX) -2.23 0.004 
SOX14 SRY (sex determining region Y)-box 14 -2.23 0.001 
ADRB1 adrenergic, beta-1-, receptor -2.23 0.007 
SEMA4C 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 4C 
-2.23 0.005 
USP2 ubiquitin specific peptidase 2 -2.22 0.019 
VANGL2 vang-like 2 (van gogh, Drosophila) -2.22 0.002 
B4GALNT3 beta-1,4-N-acetyl-galactosaminyl transferase 3 -2.22 0.022 
TBX1 T-box 1 -2.22 0.016 
WDR72 WD repeat domain 72 -2.21 0.016 
D2HGDH D-2-hydroxyglutarate dehydrogenase -2.21 0.009 
TNKS1BP1 tankyrase 1 binding protein 1, 182kDa -2.20 0.007 
KLHDC3 kelch domain containing 3 -2.20 0.001 
SCAMP5 secretory carrier membrane protein 5 -2.20 0.025 
OR2W3 olfactory receptor, family 2, subfamily W, member 3 -2.19 0.037 
XYLT1 xylosyltransferase I -2.19 0.009 
CIB2 calcium and integrin binding family member 2 -2.19 0.001 
LOC401356 similar to CG31151-PB, isoform B -2.18 0.005 
FLJ39501 cytochrome P450, family 2, subfamily E, polypeptide 2 homolog -2.17 0.006 
ARHGAP23 Rho GTPase activating protein 23 -2.15 0.035 
KCNC3 potassium voltage-gated channel, Shaw-related subfamily, member 3 -2.15 0.008 
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ICAM5 intercellular adhesion molecule 5, telencephalin -2.15 0.006 
CLN8 ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation) -2.14 0.028 
PTGS1 
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and 
cyclooxygenase) 
-2.14 0.003 
SEPT5 septin 5 -2.14 0.005 
KIAA0310 KIAA0310 -2.14 0.015 
N/A Homo sapiens cDNA FLJ36021 fis, clone TESTI2016568. -2.13 0.012 
PLA2G4F phospholipase A2, group IVF -2.13 0.036 
MDGA1 MAM domain containing glycosylphosphatidylinositol anchor 1 -2.12 0.046 
MGC12760 hypothetical protein MGC12760 -2.11 0.042 
PLEKHG5 pleckstrin homology domain containing, family G (with RhoGef domain) member 5 -2.09 0.009 
LOC402275 similar to Limbic system-associated membrane protein precursor (LSAMP) -2.09 0.008 
KCNJ9 potassium inwardly-rectifying channel, subfamily J, member 9 -2.09 0.015 
PTBP1 polypyrimidine tract binding protein 1 -2.08 0.003 
FADS2 fatty acid desaturase 2 -2.08 0.037 
ALOXE3 arachidonate lipoxygenase 3 -2.08 0.007 
DDX12 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 12 (CHL1-like helicase homolog, S. 
cerevisiae) 
-2.07 0.005 
C14orf121 chromosome 14 open reading frame 121 -2.07 0.026 
DMRTA2 DMRT-like family A2 -2.07 0.030 
FLJ14186 hypothetical gene supported by AK024248 -2.07 0.000 
KIRREL kin of IRRE like (Drosophila) -2.06 0.031 
PCDH21 protocadherin 21 -2.06 0.021 
FLJ90231 hypothetical protein FLJ90231 -2.06 0.044 
KCNK5 potassium channel, subfamily K, member 5 -2.05 0.037 
NRBP2 nuclear receptor binding protein 2 -2.05 0.001 
BCL2L2 BCL2-like 2 -2.05 0.000 
CBLN1 cerebellin 1 precursor -2.05 0.010 
NFIX nuclear factor I/X (CCAAT-binding transcription factor) -2.04 0.011 
LOC643757 hypothetical protein LOC643757 -2.04 0.013 
SLC35E2 solute carrier family 35, member E2 -2.04 0.011 
SDC3 syndecan 3 (N-syndecan) -2.03 0.008 
EPN1 epsin 1 -2.02 0.018 
CLSTN2 calsyntenin 2 -2.02 0.029 
LOC55908 hepatocellular carcinoma-associated gene TD26 -2.02 0.005 
OTOP1 otopetrin 1 -2.02 0.043 
WDR62 WD repeat domain 62 -2.02 0.028 
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit -2.01 0.007 
TNK2 tyrosine kinase, non-receptor, 2 -2.01 0.011 
FCHSD1 FCH and double SH3 domains 1 -2.01 0.012 
LOC402382 similar to collagen, type I, alpha 2 -2.01 0.002 
PLEKHH3 pleckstrin homology domain containing, family H (with MyTH4 domain) member 3 -2.01 0.014 
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TCF7 transcription factor 7 (T-cell specific, HMG-box) -2.00 0.004 
TMEM16H transmembrane protein 16H -2.00 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
59 
 
Supplementary table 2. Differentially expressed genes in chronic periodontitis group relative to 
healthy group. 
Gene 
Symbol Gene Name FC p 
Up-Regulated     
HS3ST4 heparan sulfate (glucosamine) 3-O-sulfotransferase 4 4.80 0.019 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 3.46 0.046 
KLKB1 kallikrein B, plasma (Fletcher factor) 1 2.55 0.050 
CD1B CD1b molecule 2.43 0.005 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 2.33 0.027 
SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 2.23 0.029 
NPTX2 neuronal pentraxin II 2.12 0.011 
NPY neuropeptide Y 2.03 0.040 
C1D nuclear DNA-binding protein 2.03 0.031 
Down-Regulated     
DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked -10.17 0.050 
IBSP integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II) -5.76 0.048 
CYorf15A chromosome Y open reading frame 15A -5.39 0.041 
CYorf14 chromosome Y open reading frame 14 -4.63 0.043 
DDX43 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 -4.50 0.012 
CYorf15B chromosome Y open reading frame 15B -4.46 0.028 
NLGN4Y neuroligin 4, Y-linked -4.11 0.013 
GLT1D1 glycosyltransferase 1 domain containing 1 -3.10 0.007 
SELE selectin E (endothelial adhesion molecule 1) -2.87 0.049 
LILRA1 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 -2.68 0.016 
UTY ubiquitously transcribed tetratricopeptide repeat gene, Y-linked -2.68 0.046 
ZNF533 zinc finger protein 533 -2.61 0.041 
NGFB nerve growth factor, beta polypeptide -2.54 0.034 
FCN1 ficolin (collagen/fibrinogen domain containing) 1 -2.52 0.030 
N/A Homo sapiens cDNA FLJ14320 fis, clone PLACE3000455. -2.40 0.016 
EMR1 egf-like module containing, mucin-like, hormone receptor-like 1 -2.38 0.013 
LBP lipopolysaccharide binding protein -2.35 0.048 
OR2W3 olfactory receptor, family 2, subfamily W, member 3 -2.35 0.025 
ADRB1 adrenergic, beta-1-, receptor -2.29 0.006 
EIF2A eukaryotic translation initiation factor 2A, 65kDa -2.27 0.032 
WDR72 WD repeat domain 72 -2.26 0.014 
NFE2 nuclear factor (erythroid-derived 2), 45kDa -2.25 0.020 
LOC654433 hypothetical LOC654433 -2.22 0.045 
LOC643331 similar to Kinase suppressor of ras-1 (Kinase suppressor of ras) (mKSR1) (Hb protein) -2.20 0.031 
LILRB2 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), -2.20 0.015 
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member 2 
N/A Homo sapiens mRNA -2.19 0.036 
LOC645402 similar to deubiquitinating enzyme 3 -2.18 0.038 
KIAA1383 KIAA1383 -2.18 0.004 
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) -2.18 0.028 
NLGN4X neuroligin 4, X-linked -2.10 0.029 
PAX1 paired box gene 1 -2.07 0.023 
TLR8 toll-like receptor 8 -2.04 0.097 
DMRTA2 DMRT-like family A2 -2.00 0.037 
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Supplementary table 3. Differentially expressed genes in chronic periodontitis group relative to 
aggressive periodontitis group. 
Gene Symbol Gene Name FC p 
Up-Regulated     
PSORS1C1 psoriasis susceptibility 1 candidate 1 7.27 0.009 
EGR3 early growth response 3 6.29 0.002 
ECHDC3 enoyl Coenzyme A hydratase domain containing 3 4.51 0.004 
CASP14 caspase 14, apoptosis-related cysteine peptidase 4.16 0.026 
KCNJ12 potassium inwardly-rectifying channel, subfamily J, member 12 4.09 0.001 
LOC284116 hypothetical protein LOC284116 3.87 0.003 
CCDC85B coiled-coil domain containing 85B 3.82 0.028 
ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide 3.64 0.008 
FLJ16165 FLJ16165 protein 3.64 0.025 
SMPD3 
sphingomyelin phosphodiesterase 3, neutral membrane (neutral 
sphingomyelinase II) 3.54 0.010 
HAL histidine ammonia-lyase 3.54 0.016 
HTR3A 5-hydroxytryptamine (serotonin) receptor 3A 3.46 0.018 
KLK9 kallikrein 9 3.41 0.002 
PNPLA1 patatin-like phospholipase domain containing 1 3.21 0.046 
SPRR4 small proline rich protein 4 3.05 0.045 
SERPINB12 serpin peptidase inhibitor, clade B (ovalbumin), member 12 2.9 0.012 
CYP4F11 cytochrome P450, family 4, subfamily F, polypeptide 11 2.9 0.049 
USP2 ubiquitin specific peptidase 2 2.85 0.005 
HKDC1 hexokinase domain containing 1 2.83 0.003 
SLC15A1 solute carrier family 15 (oligopeptide transporter), member 1 2.79 0.038 
ABCG4 ATP-binding cassette, sub-family G (WHITE), member 4 2.73 0.017 
IRX6 iroquois homeobox protein 6 2.7 0.021 
DLGAP1 discs, large (Drosophila) homolog-associated protein 1 2.68 0.038 
SEMA7A semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group) 2.63 0.001 
PLA2G4E phospholipase A2, group IVE 2.59 0.009 
LOC339240 keratin pseudogene 2.55 0.015 
DKK2 dickkopf homolog 2 (Xenopus laevis) 2.5 0.005 
COMP cartilage oligomeric matrix protein 2.49 0.049 
EEF1A2 eukaryotic translation elongation factor 1 alpha 2 2.48 0.012 
MAT1A methionine adenosyltransferase I, alpha 2.46 0.040 
DLX2 distal-less homeobox 2 2.42 0.040 
FLJ10781 hypothetical protein FLJ10781 2.41 0.034 
MDGA1 MAM domain containing glycosylphosphatidylinositol anchor 1 2.4 0.036 
SLC6A11 solute carrier family 6 (neurotransmitter transporter, GABA), member 11 2.39 0.007 
KIF1A kinesin family member 1A 2.38 0.006 
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LOC339240 keratin pseudogene 2.35 0.015 
SCTR secretin receptor 2.35 0.009 
ARSE arylsulfatase E (chondrodysplasia punctata 1) 2.32 0.039 
LOC644003 similar to Mucin-2 precursor (Intestinal mucin 2) 2.31 0.029 
RIMS3 regulating synaptic membrane exocytosis 3 2.31 0.045 
ALOX12B arachidonate 12-lipoxygenase, 12R type 2.31 0.029 
SLC6A17 solute carrier family 6, member 17 2.29 0.042 
BTNL9 butyrophilin-like 9 2.27 0.024 
CES4 carboxylesterase 4-like 2.27 0.016 
CALML5 calmodulin-like 5 2.26 0.016 
SP6 Sp6 transcription factor 2.26 0.007 
LOC645438 similar to CG7874-PA 2.24 0.023 
AGC1 
aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, 
antigen identified by monoclonal antibody A0122) 2.22 0.047 
RP3-402H5.2 similar to dJ402H5.2 (novel protein similar to worm and fly proteins) 2.2 0.006 
ALOXE3 arachidonate lipoxygenase 3 2.2 0.005 
LOC644193 similar to Y51B11A.1 2.16 0.036 
C1orf34 chromosome 1 open reading frame 34 2.15 0.038 
FIS FIS 2.14 0.029 
CHRFAM7A 
CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and FAM7A (family 
with sequence similarity 7A, exons A-E) fusion 2.12 0.042 
FAM83G family with sequence similarity 83, member G 2.12 0.011 
SCNN1G sodium channel, nonvoltage-gated 1, gamma 2.11 0.012 
FLJ39501 cytochrome P450, family 2, subfamily E, polypeptide 2 homolog 2.1 0.004 
SERPINA5 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 
5 2.1 0.041 
FCHSD1 FCH and double SH3 domains 1 2.09 0.008 
FLJ30934 hypothetical protein FLJ30934 2.09 0.042 
LCE3B late cornified envelope 3B 2.09 0.049 
PLA2G2F phospholipase A2, group IIF 2.09 0.009 
MFAP3L microfibrillar-associated protein 3-like 2.08 0.030 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 2.08 0.017 
TPO thyroid peroxidase 2.06 0.043 
N/A Homo sapiens cDNA FLJ44636 fis, clone BRACE2025452. 2.06 0.030 
CYP4F2 cytochrome P450, family 4, subfamily F, polypeptide 2 2.06 0.000 
XCR1 chemokine (C motif) receptor 1 2.06 0.043 
SLC26A9 solute carrier family 26, member 9 2.05 0.006 
N/A 
Homo sapiens megakaryocyte-enhanced gene transcript 1 protein (MEGT1) 
mRNA, complete cds. 2.04 0.043 
LY6H lymphocyte antigen 6 complex, locus H 2.03 0.037 
HIF3A hypoxia inducible factor 3, alpha subunit 2.02 0.037 
TAGLN3 transgelin 3 2.01 0.003 
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TRPV3 transient receptor potential cation channel, subfamily V, member 3 2.01 0.017 
Down-Regulated     
SLC35F3 solute carrier family 35, member F3 -4.3 0.042 
SELE selectin E (endothelial adhesion molecule 1) -3.9 0.039 
IL6 interleukin 6 (interferon, beta 2) -3.8 0.030 
LILRA5 
leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 
5 -3.7 0.014 
FPRL1 formyl peptide receptor-like 1 -3.5 0.013 
LOC554223 hypothetical LOC554223 -3.5 0.034 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) -3.4 0.002 
LOC440607 Fc-gamma receptor I B2 -3.3 0.004 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 -3.3 0.009 
CCL23 chemokine (C-C motif) ligand 23 -3 0.034 
LYSMD1 LysM, putative peptidoglycan-binding, domain containing 1 -3 0.008 
PSCA prostate stem cell antigen -3 0.046 
N/A Homo sapiens cDNA FLJ14320 fis, clone PLACE3000455. -3 0.004 
KLRF1 killer cell lectin-like receptor subfamily F, member 1 -2.9 0.012 
ELOVL2 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 -2.9 0.048 
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif, 3 -2.9 0.034 
TCTEX1D1 Tctex1 domain containing 1 -2.9 0.043 
APLN apelin, AGTRL1 ligand -2.9 0.017 
SH2D1B SH2 domain containing 1B -2.8 0.023 
AQP9 aquaporin 9 -2.8 0.048 
RGPD4 RANBP2-like and GRIP domain containing 4 -2.8 0.003 
LOC642681 hypothetical protein LOC642681 -2.8 0.025 
CR1L complement component (3b/4b) receptor 1-like -2.7 0.037 
TGM2 
transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) -2.7 0.020 
TLR7 toll-like receptor 7 -2.7 0.007 
GLT1D1 glycosyltransferase 1 domain containing 1 -2.7 0.014 
SIGLEC7 sialic acid binding Ig-like lectin 7 -2.6 0.017 
LPPR4 plasticity related gene 1 -2.6 0.027 
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 -2.6 0.037 
ZNF229 zinc finger protein 229 -2.5 0.022 
CD300LF CD300 molecule-like family member f -2.5 0.022 
ARHGAP20 Rho GTPase activating protein 20 -2.5 0.050 
CSTL1 cystatin-like 1 -2.5 0.024 
EMR1 egf-like module containing, mucin-like, hormone receptor-like 1 -2.5 0.010 
LOC653127 similar to GTPase activating Rap/RanGAP domain-like 4 -2.5 0.014 
N/A Homo sapiens cDNA FLJ38999 fis, clone NT2RI2021625. -2.5 0.020 
CNDP1 carnosine dipeptidase 1 (metallopeptidase M20 family) -2.4 0.015 
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C9orf26 chromosome 9 open reading frame 26 (NF-HEV) -2.4 0.019 
LOC148203 hypothetical protein LOC148203 -2.4 0.010 
GARNL4 GTPase activating Rap/RanGAP domain-like 4 -2.4 0.015 
CAPS2 calcyphosine 2 -2.4 0.013 
EIF2A eukaryotic translation initiation factor 2A, 65kDa -2.4 0.024 
LILRA1 
leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 
1 -2.4 0.030 
NRCAM neuronal cell adhesion molecule -2.4 0.050 
TLR8 toll-like receptor 8 -2.4 0.050 
ELOVL3 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 -2.4 0.018 
LOC653489 
similar to Ran-binding protein 2 (RanBP2) (Nuclear pore complex protein 
Nup358) (Nucleoporin Nup358) (358 kDa nucleoporin) (P270) -2.3 0.011 
FLJ13391 hypothetical protein FLJ13391 -2.3 0.050 
ZNF718 zinc finger protein 718 -2.3 0.018 
ALPK2 alpha-kinase 2 -2.3 0.027 
LEMD1 LEM domain containing 1 -2.3 0.000 
FLJ44054 hypothetical protein LOC643364 -2.3 0.027 
OLR1 oxidised low density lipoprotein (lectin-like) receptor 1 -2.3 0.044 
DNM3 dynamin 3 -2.2 0.014 
FLJ45743 hypothetical protein LOC642484 -2.2 0.028 
FLJ42461 FLJ42461 protein -2.2 0.007 
HGF hepatocyte growth factor (hepapoietin A -2.2 0.002 
C12orf36 chromosome 12 open reading frame 36 -2.2 0.036 
GDF9 growth differentiation factor 9 -2.2 0.039 
KIAA1383 KIAA1383 -2.2 0.004 
KLHL4 kelch-like 4 (Drosophila) -2.2 0.007 
CLDN23 claudin 23 -2.2 0.033 
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) -2.2 0.023 
NFE2 nuclear factor (erythroid-derived 2), 45kDa -2.2 0.025 
FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) -2.2 0.047 
ACVR1C activin A receptor, type IC -2.1 0.037 
NNMT nicotinamide N-methyltransferase -2.1 0.022 
LOC387647 hypothetical gene supported by BC014163 -2.1 0.004 
LAMA1 laminin, alpha 1 -2.1 0.007 
SDS serine dehydratase -2.1 0.045 
FLJ46875 hypothetical LOC440918 -2.1 0.048 
ZNF542 zinc finger protein 542 -2.1 0.014 
PDE4D 
phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, 
Drosophila) -2.1 0.021 
CPNE8 copine VIII -2.1 0.050 
IL1B interleukin 1, beta -2.1 0.048 
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) -2.1 0.033 
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PCDH17 protocadherin 17 -2.1 0.041 
LOC653043 similar to cell recognition molecule CASPR3 -2.1 0.020 
LOC345079 similar to RIKEN cDNA 5730467H21 -2.1 0.020 
N/A 
Homo sapiens mRNA similar to LOC166173 (cDNA clone MGC:34832 
IMAGE:5203730), complete cds. -2.1 0.005 
FNDC3B fibronectin type III domain containing 3B -2.1 0.038 
GCKR glucokinase (hexokinase 4) regulator -2.1 0.035 
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 -2 0.001 
LOC643331 
similar to Kinase suppressor of ras-1 (Kinase suppressor of ras) (mKSR1) (Hb 
protein) -2 0.046 
C4orf18 chromosome 4 open reading frame 18 -2 0.031 
SLC15A2 solute carrier family 15 (H+/peptide transporter), member 2 -2 0.014 
CERKL ceramide kinase-like -2 0.028 
SEMA6B 
sema domain, transmembrane domain (TM), and cytoplasmic domain, 
(semaphorin) 6B -2 0.001 
LOC643194 hypothetical protein LOC643194 -2 0.043 
DKFZP566N034 hypothetical protein DKFZp566N034 -2 0.033 
LOC646373 hypothetical protein LOC646373 -2 0.024 
CLDN22 claudin 22 -2 0.016 
LOC643355 hypothetical protein LOC643355 -2 0.049 
CREB5 cAMP responsive element binding protein 5 -2 0.037 
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Supplementary table 4. Gene Ontology Groups differentially expressed in aggressive periodontitis 
group relative to healthy group. 
Group Name ID p-value Count 
% 
regulated 
Up-Regulated         
Cellular defense response GO:0006968 2,3E-7 6 12,8 
Response to stimulus GO:0050896 3,3E-5 20 42,6 
Defense response GO:0006952 5,2E-5 9 19,1 
Immune response GO:0006955 1,2E-4 9 19,1 
Immune system process GO:0002376 2,7E-4 10 21,3 
Response to stress GO:0006950 3,1E-2 9 19,1 
Natural killer cell activation GO:0030101 4,7E-2 2 4,3 
Down-Regulated         
neurotransmitter transport GO:0006836 2,2E-5 7 5,6 
secretion GO:0046903 1,1E-3 9 7,2 
nervous system development GO:0007399 1,1E-3 18 14,4 
developmental process GO:0032502 2,8E-3 35 28,0 
generation of a signal involved in cell-cell signaling GO:0003001 2,8E-3 5 4,0 
transmission of nerve impulse GO:0019226 2,8E-3 9 7,2 
secretion by cell GO:0032940 3,0E-3 7 5,6 
synaptic transmission GO:0007268 4,4E-3 8 6,4 
multicellular organismal development GO:0007275 4,5E-3 32 25,6 
anatomical structure development GO:0048856 5,3E-3 29 23,2 
system development GO:0048731 6,8E-3 27 21,6 
multicellular organismal process GO:0032501 8,2E-3 42 33,6 
phospholipid catabolic process GO:0009395 
9,9E-3 3 2,4 
neuron differentiation GO:0030182 1,1E-2 9 7,2 
regulation of neurotransmitter levels GO:0001505 1,1E-2 4 3,2 
cellular developmental process GO:0048869 1,1E-2 21 16,8 
fatty acid biosynthetic process GO:0006633 1,7E-2 4 3,2 
cell-cell signaling GO:0007267 2,2E-2 10 8,0 
neurotransmitter secretion GO:0007269 2,3E-2 3 2,4 
unsaturated fatty acid biosynthetic process GO:0006636 2,3E-2 3 2,4 
potassium ion transport GO:0006813 2,4E-2 5 4,0 
peripheral nervous system development GO:0007422 2,5E-2 3 2,4 
system process GO:0003008 2,7E-2 18 14,4 
cell projection morphogenesis GO:0048858 2,7E-2 6 4,8 
localization GO:0051179 2,7E-2 30 24,0 
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cellular lipid metabolic process GO:0044255 
2,8E-2 9 7,2 
cell differentiation GO:0030154 2,9E-2 19 15,2 
regulation of blood pressure GO:0008217 3,2E-2 4 3,2 
cell part morphogenesis GO:0032990 3,2E-2 6 4,8 
cell morphogenesis GO:0000902 3,6E-2 7 5,6 
ion transport GO:0006811 3,8E-2 11 8,8 
generation of neurons GO:0048699 3,8E-2 9 7,2 
tissue development GO:0009888 3,9E-2 10 8,0 
blood circulation GO:0008015 3,9E-2 5 4,0 
circulatory system process GO:0003013 3,9E-2 5 4,0 
regulation of norepinephrine secretion GO:0014061 4,1E-2 2 1,6 
metal ion transport GO:0030001 4,1E-2 8 6,4 
axonogenesis GO:0007409 4,4E-2 5 4,0 
cell communication GO:0007154 4,6E-2 11 8,8 
unsaturated fatty acid metabolic process GO:0033559 4,8E-2 3 2,4 
organ development GO:0048513 4,8E-2 19 15,2 
transport GO:0006810 5,0E-2 26 20,8 
regulation of secretion GO:0051046 5,0E-2 5 4,0 
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Supplementary table 5. Gene Ontology Groups differentially expressed in chronic periodontitis 
group relative to healthy group. 
Group Name ID p-value Count 
% 
regulated 
Up-Regulated         
Regulation of proteolysis GO:0030162 3,0E-2 2 22,2 
Antigen processing and presentation GO:0019882 4,6E-2 2 22,2 
Regulation of response to external stimulus GO:0032101 8,7E-2 2 22,2 
Down-Regulated         
defense response 
 
1,4E-3 6 20,0 
immune system process 
 
2,0E-3 7 23,3 
multi-organism process 
 
2,2E-3 6 20,0 
cell adhesion 
 
2,5E-3 6 20,0 
biological adhesion 
 
2,5E-3 6 20,0 
response to lipopolysaccharide 
 
5,2E-3 3 10,0 
response to wounding 
 
5,9E-3 5 16,7 
response to stress 
 
6,5E-3 8 26,7 
response to molecule of bacterial origin 
 
6,5E-3 3 10,0 
response to other organism 
 
7,6E-3 4 13,3 
positive regulation of metabolic process 
 
8,0E-3 6 20,0 
opsonization 
 
8,5E-3 2 6,7 
inflammatory response 
 
1,0E-2 4 13,3 
cell surface receptor linked signal transduction 1,1E-2 8 26,7 
response to stimulus 
 
1,3E-2 11 36,7 
immune response 
 
1,5E-2 5 16,7 
immune effector process 
 
1,5E-2 3 10,0 
cellular component organization 
 
1,6E-2 9 30,0 
response to biotic stimulus 
 
1,6E-2 4 13,3 
regulation of defense response 
 
1,7E-2 3 10,0 
regulation of interleukin-8 production 
 
2,1E-2 2 6,7 
detection of biotic stimulus 
 
2,5E-2 2 6,7 
response to bacterium 
 
3,0E-2 3 10,0 
response to external stimulus   3,7E-2 5 16,7 
 
 
 
 
  
69 
 
Supplementary table 6. Gene Ontology Groups differentially expressed in chronic periodontitis 
group relative to aggressive periodontitis. 
Group Name ID p-value Count % regulated 
Up-Regulated         
phospholipid catabolic process GO:0009395 3,4E-3 3 4,3 
leukotriene metabolic process GO:0006691 3,4E-3 3 4,3 
cellular alkene metabolic process GO:0043449 3,7E-3 3 4,3 
lipid catabolic process GO:0016042 4,9E-3 5 7,1 
epidermis development GO:0008544 6,1E-3 5 7,1 
ectoderm development GO:0007398 7,9E-3 5 7,1 
icosanoid metabolic process GO:0006690 1,5E-2 3 4,3 
unsaturated fatty acid metabolic process GO:0033559 1,7E-2 3 4,3 
cellular lipid metabolic process GO:0044255 1,7E-2 7 10,0 
ion transport GO:0006811 3,1E-2 8 11,4 
cellular lipid catabolic process GO:0044242 3,7E-2 3 4,3 
metal ion transport GO:0030001 3,7E-2 6 8,6 
phospholipid metabolic process GO:0006644 4,0E-2 4 5,7 
lipid metabolic process GO:0006629 4,1E-2 8 11,4 
neurotransmitter transport GO:0006836 4,3E-2 3 4,3 
organophosphate metabolic process GO:0019637 4,5E-2 4 5,7 
transport GO:0006810 4,6E-2 17 24,3 
tissue development GO:0009888 4,7E-2 7 10,0 
establishment of localization GO:0051234 5,0E-2 17 24,3 
Down-Regulated         
immune response GO:0006955 5,0E-6 14 16,7 
immune system process GO:0002376 1,3E-5 16 19,0 
cell adhesion GO:0007155 3,1E-5 13 15,5 
biological adhesion GO:0022610 3,2E-5 13 15,5 
inflammatory response GO:0006954 6,5E-5 9 10,7 
response to wounding GO:0009611 7,1E-5 11 13,1 
defense response GO:0006952 2,4E-4 11 13,1 
locomotion GO:0040011 4,5E-4 9 10,7 
cell-cell adhesion GO:0016337 1,1E-3 7 8,3 
response to external stimulus GO:0009605 1,4E-3 12 14,3 
positive regulation of interleukin-6 production GO:0032755 2,9E-3 3 3,6 
regulation of defense response GO:0031347 3,2E-3 5 6,0 
defense response to virus GO:0051607 3,2E-3 3 3,6 
positive regulation of defense response GO:0031349 3,7E-3 4 4,8 
regulation of cytokine biosynthetic process GO:0042035 3,8E-3 4 4,8 
cell motion GO:0006928 3,9E-3 8 9,5 
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taxis GO:0042330 4,7E-3 5 6,0 
chemotaxis GO:0006935 4,7E-3 5 6,0 
regulation of response to stress GO:0080134 6,1E-3 6 7,1 
leukocyte adhesion GO:0007159 6,3E-3 3 3,6 
cell migration GO:0016477 6,3E-3 6 7,1 
cell motility GO:0048870 9,7E-3 6 7,1 
localization of cell GO:0051674 9,7E-3 6 7,1 
regulation of interleukin-6 production GO:0032675 1,0E-2 3 3,6 
positive regulation of interferon-alpha biosynthetic process GO:0045356 1,7E-2 2 2,4 
cell morphogenesis GO:0000902 1,7E-2 6 7,1 
positive regulation of cytokine biosynthetic process GO:0042108 1,8E-2 3 3,6 
positive regulation of response to stimulus GO:0048584 1,8E-2 5 6,0 
response to chemical stimulus GO:0042221 1,8E-2 12 14,3 
cell morphogenesis involved in differentiation  GO:0000904 2,0E-2 5 6,0 
positive regulation of interferon-beta biosynthetic process GO:0045357 2,1E-2 2 2,4 
regulation of interferon-beta biosynthetic process GO:0045354 2,1E-2 2 2,4 
regulation of interferon-alpha biosynthetic process GO:0045354 2,1E-2 2 2,4 
response to stress GO:0006950 2,3E-2 14 16,7 
leukocyte migration GO:0050900 2,4E-2 3 3,6 
cellular component morphogenesis GO:0032989 2,6E-2 6 7,1 
response to stimulus GO:0050896 2,7E-2 23 27,4 
organic acid biosynthetic process GO:0016053 2,8E-2 4 4,8 
carboxylic acid biosynthetic process GO:0046394 2,8E-2 4 4,8 
locomotory behavior GO:0007626 2,9E-2 5 6,0 
positive regulation of interleukin-8 biosynthetic process GO:0045416 2,9E-2 2 2,4 
regulation of interferon-alpha production GO:0032647 3,4E-2 2 2,4 
response to other organism GO:0051707 3,5E-2 5 6,0 
cytokine-mediated signaling pathway GO:0019221 3,6E-2 3 3,6 
positive regulation of molecular function GO:0044093 3,8E-2 7 8,3 
regulation of interleukin-8 biosynthetic process GO:0045414 3,8E-2 2 2,4 
regulation of vascular endothelial growth factor production GO:0010574 3,8E-2 2 2,4 
regulation of inflammatory response GO:0050727 4,1E-2 3 3,6 
regulation of cytokine production GO:0001817 4,2E-2 4 4,8 
regulation of chemokine biosynthetic process GO:0051239 4,2E-2 2 2,4 
regulation of multicellular organismal process GO:0051239 4,4E-2 9 10,7 
cell surface receptor linked signal transduction GO:0007166 4,5E-2 14 16,7 
positive regulation of interferon-gamma biosynthetic 
process GO:0045078 
4,6E-2 2 2,4 
regulation of response to stimulus GO:0048583 4,7E-2 6 7,1 
activation of MAPK activity GO:0000187 4,7E-2 3 3,6 
Behavior GO:0007610 4,9E-2 6 7,1 
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Conclusão 
 
Dentro dos limites do presente estudo, pode-se concluir que: 
 
i) A grande quantidade de dados gerados através das tecnologias 
ômicas (genômica, transcriptômica, proteômica e metabolômica) 
permite a identificação de novas moléculas e vias metabólicas 
envolvidas no equilíbrio entre saúde e doença periodontal, 
aumentando a compreensão da patogênese das periodontites. 
Consequentemente, elas podem ser aplicadas futuramente no 
diagnóstico das periodontites, através da identificação de um ou 
mais biomarcadores para detecção de doença ativa, predizer sua 
futura progressão, e avaliar a resposta ao tratamento periodontal. 
Melhorando assim o manejo clínico dos pacientes através de 
cuidados personalizados, ao permitir detecção e intervenção 
precoce.    
ii) A análise do microarray e a mineração de dados demonstraram 
que a periodontite crônica, e especialmente a periodontite 
agressiva apresentam diferenças no perfil de expressão gênica 
tecidual entre si e em comparação com indivíduos sem histórico 
de periodontite. Indicando que essas doenças podem apresentar 
diferentes vias e mecanismos de destruição periodontal.  
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